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General introduction
CHAPTER 1
General Introduction and Outline of the Thesis
CHAPTER I
INTRODUCTION
Since antibiotics became clinically available in the 1940s, they have been used as safe
magic bullets to treat bacterial infections without risk for the treated patients "".
Already at the start of antibiotic therapy, bacteria with acquired resistance against
antibiotics were isolated, though very rarely. In the passing decades however,
susceptible bacteria have been eliminated by the increasing amounts of antibiotics they
have been exposed to and only unsusceptible species and strains with resistance
mechanisms to ward of destruction were able to survive and replaced the original
susceptible population. The rise of antibiotic resistance in bacteria has become a
world-wide and increasing public health problem, as infections caused by resistant
bacteria arc often resistant to more than one antibiotic, and arc therefore difficult to
treat and to control *". Indeed in some countries the unacceptable situation has been
reached that the majority of hospital isolates of Gram-negative enteric bacteria,
staphylococci and cnterococci have become resistant to most, formerly effective,
antibiotics. In Table I an overview of the emergence of resistance after the discovery
and introduction of an antibiotic agent is displayed. Until recently, new antibiotics
have always appeared just in the nick of time, before resistance problems got out of
hand. However, now the increasingly rapid pace at which bacteria develop and acquire
new drug resistance profiles, seem to outpace the rate at which the pharmaceutical
industry is able to develop and market new antibiotics "\
EMERGENCE OF ANTIBIOTIC RESISTANCE
Bacteria can be unsusceptible or intrinsically resistant, which means that a whole
species or genus is not susceptible to a certain antibiotic. Acquired resistance is the
phenomenon thai certain bacteria belonging to a susceptible species are not inhibited
or killed any more by concentrations of an antibiotic that would normally do so. There
arc two ways to acquire resistance, by chromosomal mutation or by acquisition of
exogenous genes. The potential for antibiotic resistance by chromosomal mutation is
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intrinsic to all bacteria, because it occurs spontaneously in replicating bacteria due to
the imperfect fidelity of DNA replication, and is therefore not influenced by the
presence of antibiotics. Indeed, even before antibiotics became clinically available
resistant bacteria could be found in soil, intestinal flora and clinical isolates, but only
in very small numbers *• '*. Resistance by gene acquisition generally refers to the prior
existence of a resistance gene that is then acquired by another bacterium *•* through
transformation, conjugation, or transduction. Resistance genes can be found on the
bacterial chromosome, or are carried on plasmids, that by conjugation can transfer
itself to other bacteria, even of different species. The resistance genes are found on
plasmids which are embedded in small DNA units called transposons. that easily hop
within one bacteria between its chromosome and plasmids present and even from
bacteria to bacteria.
TABLE 1. The emergence of resistance after the introduction of an antibiotic »gent.
Antibiotic Discovered Clinically available Observed resistance
1940
1965
1947, 1956
1956
1956
1987
1966
1970
1985
1985
Penicillin
Methicillin
Streptomycin
Tctracycline
Erythromycin
Vancomycin
Nalidixic acid
Gentamicin
Third-generation
Cephalosporins
Fluoroquinonlones
1940
1944
1948
1952
1956
1960
1963
1956
1978
1943
1961
1947
1952
1955
1972
1962
1967
1980
1982
Adapted from EMLA 1999
/?«/5/a/tc? »if cAa/i/.v ms
Resistance genes give rise to antibiotic degrading or chemically modifying enzymes
inactivating the drug, or enzymes that can eliminate the drug's target, entry ports, or
can manufacture pumps that export antibiotics. In Table 2 various resistance
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mechanisms and the way they can be acquired are presented with examples of the
affected antibiotics.
TABLE 2. Biochemical mechanisms of antibiotic resistance and their genetic determinants.
Genetic determinants
Mechanisms
Reduced permeability
Active efflux
Alteration of drug target
'By-pats' inhibited step
Inactivation of drug
Amplification of target
Sequestration of drug
Examples
Aminoglycosides
Tetracycline
Fluoroquinolones
F.rythromycin
Fluoroquinolones
Rifampin
Tetracycline
Sulfonamidcs
Trimcthoprim
Aminoglycosides
Chloramphenicol
ß-lactams
Trimcthoprim
Sulfonamides
ß-lactams
Mutation Gene acquisition
Adapted fh>m Davies 1997'"
Due to mutations or acquisition of resistance genes, a minority of bacteria resistant to a
certain antibiotic may be present in a population. Whether these resistant strains will
survive and replicate depends in large degree on the selection pressure being present.
If due to the increasing use of antibiotics the susceptible bacteria are eliminated, their
resistant kin will replace them and the majority of the population will become
resistant. If the selection pressure is removed the resistant bacteria may be replaced
again by susceptible bacteria for two reasons: introduction of new susceptible bacteria
from the environment and because resistant bacteria are less "fit". This means that they
often have longer generation times and are less adaptable than their susceptible
8
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relatives. Hence in the absence of continuing selection of antibiotics in the community,
the key factor driving a decrease in antibiotic resistance may be the 'fitness cost' of
resistance i.e. resistance will decline after a reduction in antibiotic use if resistant
organisms are at a disadvantage for transmission or persistence *' **. In contrast, in
hospitals a change in resistance levels will be primarily driven by the admission of
new patients which often bring with them drug-susceptible flora, which may 'dilute'
levels of resistance in the absence of continuing selection of antibiotics '**.
Next to selection pressure of antibiotic use. the dissemination of resistant buclcna und
resistance genes is a very important factor for antibiotic resistance to spread.
Dissemination of genetic bacteria through direct or indirect contact with other
individuals may lead to colonisation by drug-resistant bacteria or transfer of resistance
genes to the endogenous flora from one individual to another.
The excessive use of antibiotics by mankind has led to the excretion of large numbers
of antibiotic resistant bacteria into the environment enhancing the chance of
colonisation and infection to spread among individuals \ (Especially in places where
the density of hosts (humans or animals) and antibiotic usage is high and breaches in
hygienic barriers are likely to occur (hospitals, day care centers, nursing homes and
animal farms), antibiotic resistant bacteria and resistant genes can easily disseminate
from one host to another.
Administration of an antimicrobial agent may not only kill the pathogen but will also
change the composition of the commensal flora. Even though pathogenic bacteria
cause problems in treating a patient when resistant, and form a tangible threat for
public health, commensal bacteria arc just a well exposed to selection and
dissemination. Benign commensal bacteria that lack the relevant resistance will die,
and those that are intrinsic non-susceptible or by chance, have acquired the relevant
resistant gene will proliferate and expand into the niche abandoned by the
exterminated susceptible bacteria **.
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The high numbers of bacteria and the many species present make the intestinal tract of
man and animals an ideal setting for gene exchange. An entering pathogen and a
passing trough non-pathogenic bacterium might obtain resistance genes from the
commensal flora even without colonising **. Therefore the commensal flora is a very
important and underestimated reservoir of resistant bacteria and genes for pathogenic
bacteria.
SURVEILLANCE OF ANTIBIOTIC USE AND RESISTANCE
The main objectives of antimicrobial resistance surveillance programs are to provide
baseline data describing the prevalence of resistance within populations and
assessment how this responds over time to changes in selective pressure from
antibiotic use. Also changes due to interaction with other populations as a result of
exchange of resistant bacteria or resistance genes between populations and the effects
of interventions are assessed. This is called resistance epidemiology.
Next to the surveillance of resistance prevalence in clinical isolates, an alternative and
fast increasing approach is surveillance based on the prevalence of resistance in the
endogenous flora of populations. It is widely considered that most infections in a
population result from the commensal flora carried within a population. Moreover
resistant bacteria of the endogenous flora not only constitute an enormous reservoir of
resistance genes for (potentially) pathogenic bacteria, but also the level of resistance in
the endogenous flora is considered to be a good indicator for the selection pressure
exerted by antibiotic use on a population and for resistance problems to be expected in
pathogens.
The use of indicator bacteria of the endogenous flora, like EvcAmcA/a co/i and
enterococei in faecal samples of randomly selected individuals of a population makes
it not only feasible to measure the selective pressure of antibiotic use in that
population, but also to compare the prevalence of resistance in different populations
and to detect transfer of resistance from one population to another. £. CYJ// and
enterococi belong to the endogenous flora of humans and most animal species, making
comparison between populations of both sources possible.
10
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RESERVOIRS OF RESISTANCE
The extent of antibiotic resistance in a population is strongly correlated with the level
of antibiotic usage and the ease with which bacteria can disseminate: crowding and
poor sanitary levels \ Hospitals are traditionally the major breeding grounds of
resistant bacteria **. The large amounts of antibiotics patients are exposed to in
hospitals " and the relatively high patient density and frequent contact with healthcare
workers, who can act as suitable vectors, ** makes the hospital environment a place for
resistance to be easily spread *'• *". In addition, underlying illnesses and therapeutic
interventions that may cause immunosuppression make a hospitalised patient more
prone to colonisation and infection by (resistant) bacteria "•*'. Comparable situations
of susceptible hosts crowded together with inevitable breaches in hygiene arc found in
day care centres and nursing homes *\ facilitating the dissemination of antibiotic
resistant bacteria and resistance genes.
Antibiotic use. Even though the antibiotic use in hospitals and nursing homes is high,
by far most antibiotics (approximately 80%) are consumed by humans in the open
population \ This extensive use of antibiotics is another reason why the commensal
flora of healthy individuals is such an important reservoir of resistant bacteria. Large
differences in the amount and types of antibiotics consumed in the community are
observed between countries. Reasons for this are among other factors differences in
prescribing habits, antibiotic policies and socio-economic and cultural aspects '• "' '".
Not surprisingly, also large differences in the prevalence of antibiotic resistance are
observed between countries. Also within one country antibiotic consumption and
consequently prevalence of antibiotic resistance can vary considerably " •" . ^ which
emphasizes the generally accepted relation between antibiotic use and prevalence of
resistance. In addition various studies have described the effectiveness of altering
antibiotic prescribing policies on antibiotic resistance '^ ' '*'*'" *\
11
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Dissemination. Acquisition of drug-resistant bacteria through contact with other
individuals has not been as extensively investigated in the community as it has been in
hospitals, but there is certainly evidence showing this to occur in the home situation '*•
17, 47,55 ^ vvell as in other community environments, such as day care centres " . A
higher prevalence of resistance has also been observed among persons living in close
contact with pigs and poultry. Several studies showed that pig and poultry farmers
have a much higher prevalence and degree of resistance in their intestinal flora
compared to urban residents living in the same geographic region. Moreover £. co//
and cnlcrococci with identical genotypes were isolated from animals and farmers
which strongly suggests clonal transmission **\ Poultry and pork were also suggested
as a possible source of quinolonc resistant £.vc-/>mW>/a co// in the community in
Barcelona, where 26% of children were found to be faecal carriers of these organisms
despite apparently never having been exposed to quinolones '*. This clearly shows that
living in an environment with resistant bacteria is a real risk for acquiring such
bacteria and that the closer the contact the larger the risk. Similar to living in close
contact with animals one could speculate that living in close contact with other persons
harbouring resistant micro-organisms or resistant genes is a risk factor to acquire
antibiotic resistance in the community.
Next to the antibiotic use in human medicine (in the Netherlands approximately
80.000 kgs active ingredient at 100 % purity per year) a large part of antibiotics is used
in animal husbandry for therapy (300.000 kgs) and for mere economic reasons to
increase growth of animals as so called antimicrobial growth promoters
(approximately 250.000 kgs) ". This has resulted in a large reservoir of resistant
bacteria and genes in the intestinal tract of farm animals. Despite high standards of
hygiene during the slaughtering process, contamination of meat and meat products by
the intestinal flora of slaughtered animals cannot be completely avoided. Hence faecal
(resistant) bacteria of food animals can reach humans through the food chain "*' *'.
Genetically identical bacteria have been found in food animals, meat products " ,
farmers"' ''" "* outpatients, and hospitalised patients suggesting that transmission
12
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between animals and humans can occur and may contribute to colonisation and
subsequently infection in humans **'**.
The dissemination of antibiotic resistant bacteria and resistance genes between hosts is
not only confined to a specific reservoir. Bacteria and consequently resistance know
no borders, and do not stop at a hospital door, or an animal farm. For example, when
patients are discharged, hospital acquired resistance is taken home und might
contribute to the dissemination of resistance genes and resistant bacteria in the
community. In addition, resistant bacteria or resistance genes can also be introduced in
a population from far away countries by tourists and visitors, like animal bacteria (hat
can reach the community via foods of animal origin.
The interaction of all these resistance reservoirs takes mainly place in the community
and in addition, most human antibiotic use is in the community. Also resistant bacteria
and their resistance gene found in the hospital have been once introduced from the
community into the hospital. Therefore the prevalence and degree of antibiotic
resistance in the community occupies a key position in resistance epidemiology and is
to be considered as a very important source to monitor. It represents the prevalence of
antibiotic resistance in general, and consequently provides a basis for antibiotic
prescribing and infection control policies. In addition, it also represents resistance
problems that might be encountered in hospitals as inevitably, healthy individuals
living in the community will at some point have to attend a general practitioner or will
be admitted to a hospital.
ANTIBIOTIC RESISTANCE IN FAECAL £5CTf£ff/C/?//4 CO/./
A limited number of studies have been performed determining the prevalence of
resistant faecal £. co// in healthy volunteers and hospitalised patients. In general, high
prevalences of resistant faecal £. co// against amoxicillin, oxytetracyclinc and
trimethoprim have been isolated from healthy volunteers in various European
13
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countries "' '*•*• **• "• "• ™, the USA ' \ South America * ** and developing countries '•
**•"•", varying between l2%-89%, 14%-68%, and 9%-45% respectively. In addition,
several studies have shown that children and the elderly are populations with a higher
risk for colonization of their commensal flora by resistant and even multidrug resistant
A'.ru// *' '*" ™ due to the high risk environment for acquisition of resistant bacteria and
resistance genes provided by day-care centres and nursing homes respectively. Not
surprisingly, the hospital environment has also been shown to effect the commensal
flora of patients. " • "
ANTIBIOTIC RESISTANCE IN FAECAL ENTEROCOCCI
Most research on the resistance prevalence of faecal enterococci has been focused on
the prcvulence of vancomycin resistance in healthy volunteers and hospitalised
patients. In KU countries vancomycin resistant enterococci (VRE) are relatively
frequently found in "healthy" individuals in the community and in farm animals,
whereas VRE still seem to be very uncommon in hospitals "•"•"'•' '-•".
The considerable pool of transmissible vuw/1-mediated glycopeptide resistance in the
EU community is most likely caused by the abundant use of avoparcin (a glycopeptide
like vancomcyin) in the recent past for growth promotion in animals ^ *"'. In April
1997, the European Commission suspended the use of avoparcin in animals. Denmark
had already forbidden its use in 1995 and Germany in 1996. Within 2 years of
stopping the use of avoparcin in The Netherlands, not only the number of VRE in the
faecal flora of food animals but also of healthy humans significantly decreased **.
Similarly, a decrease in the number of VRE in poultry (meats) was found in Denmark,
Germany and Italy after the ban of avoparcin , whereas in Norwegian poultry the
number of VRE has remained high three years after the ban " " . In Germany the
number of VRE in faecal samples of healthy humans also decreased from 12% (1994)
to 3% (1997), and in Belgium the percentage of VRE carriers in hospitals decreased
from 12% in 1996 to less than 1% in 2001 '*.
In contrast with the EU. alarming situations of infections due to VRE are found in
USA hospitals, whereas a community reservoir is absent *. Vancomycin resistance in
14
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these hospital isolates is as commonly of the Ta/iÄ as of the Fcin^-type. As avoparein
does not select for r<j/jfi-resistance in enterococci this paradox is probably caused by
the high use of vancomycin in the US hospitals. A comparison of the US with Europe,
showed that yearly usage of vancomycin, both injectable and oral forms, was five to
tenfold higher in the USA *'.
The existence in the EU of a large pool (reservoir) of enterococci with transnosons
carrying the ran/4 gene cluster might endanger public health. Next to the fact that
infections by VRE are difficult to treat, it might also hold a risk for transfer of the
Kart/4 gene cluster to staphylococci. This has been shown to be possible m vi/m and in
experimental animals, and has recently unfortunately also happened in u hospital
patient in the USA. **•*'
The ability to identify accurately the strains of infectious agents thut cause disease is
central to epidemiological surveillance and public health decisions. Molecular typing
methods are used to address two very different kinds of problem. First to trace the
transmission and dissemination of strains in intra- and inter-hospital outbreaks and
second in resistance epidemiology to determine the genetic rclatedness between
isolates of which the relatedness is not directly clear. Because of the high degree of
strain differentiation, pulsed-field gel clectrophorcsis (PFGE) is able to identify the
microvariation that is needed to distinguish between strains circulating within a
geographic area and has therefore been considered the reference standard for studying
individual outbreaks in a hospital. However PFGE is too discriminatory to establish
the degree of genetic relatedness between epidemiological nonrclatcd strains, because
the banding patterns of such strains are often completely different. Therefore, using
PFGE is a too insensitive method to allow disclosure of strain-characteristic
differences in the host specificity of enterococci, as it fails to see the forest for the
trees"-™.
Amplified-fragment length polymorphism analysis (AFLP) allows for the analysis of
polymorphism among small restriction fragments and is based on selective
amplification of restriction fragments generated from total genomic DNA '*. The
15
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advantage of AFLP typing is that these small restriction fragments originate from both
variable and conserved DNA sequences, thus establishing a degree of genetic
relatcdness that, by PFGE. would show no similarity at all.
Various developed molecular techniques like PFGE, RFLP (PCR-restriction fragment
length polymorphism), ribotyping, and random amplified polymorphic DNA analysis
often lack adequate discriminatory power, and the rcproducibility is poor. Whereas
AFLP can be easily automated, which allows standardization and high throughput of
strains in epidcmiological investigations. Moreover, digitisation of the data results in
easy storage, cross-referencing, and exchange of data between laboratories '*.
However, AFLP data may be less suitable for global epidemiology, as variations in
band intensities can easily occur between laboratory causing a source of ambiguities
when curve based similarity coefficients like the Pearson correlation are used to
compare banding patterns "\ For studying the global epidemiology, recognition and
trucking world-wide, the most appropriate technique is multilocus sequence typing
(MLST). as MLST is based on identifying alleles from DNA sequences of internal
fragments of housekeeping genes, and is pre-eminently useful for electronic data ' \
' I'/I
Molecular typing has revealed genetically related VRE isolates in food animals, meat
products '•', outpatients, and hospitalised patients suggesting that transmission between
animals und humans can occur and may contribute to colonisation and subsequently
infection in humans ^'**' ™. Molecular comparison by pulsed-field gel electrophoresis
(PFGb) "•"•*' '"*"'". and amplificd-fragment length polymorphism (AFLP) analysis "'™
of human- and animal-derived £w/m>iweMs /aec/i/m revealed the existence of a
common human and pig genogroup. while poultry derived VREF clustered in a
separate genogroup. However, identical genotypes of several enterococcus species by
PFGE have been isolated from poultry' and poultry farmers, but especially typing of
the Tn/.Wrt transposon " ***' * ' " *"' *" showed that identical Tn/.Wri derivatives were
found in humans and poultry suggesting horizontal spread of the van.4 transposon from
poultry to human.
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CONCLUSIONS
The emergence of antibiotic resistant bacteria driven by the interplay of many
mechanistic and epidemiological factors is very complex. Mechanistically, resistance by
target alteration, reduced permeability, and drug inactivation can occur by both
chromosomal mutation and acquisition of new genetic elements. Epidemiologically.
exposure to antimicrobial agents provides a growth and persistence advantage for any
existing resistant bacteria, generally irrespective of the mechanism **.
Sixty years of lavish usage of antibiotics in human and veterinary medicine and in
agriculture has progressively eroded the clinical efficiency of antibiotics because of a
rising tide of acquired resistance in pathogenic bacteria. In addition resistance observed
in pathogenic bacteria is only the top of the resistance iceberg and an enormous reservoir
of resistance genes has accumulated in the intestinal flora of man and other animals.
Despite that emergence of resistance is an inevitable sequel of antibiotic use, there is
fortunately a growing national and international concern about the increasing resistance
and the need for more concerted action to prevent, delay and control bacterial resistance
against antibiotics is generally recognised. As interventions should be based on
scientifically based decisions, resistance epidemiology should be considered the
cornerstone in the control of antibiotic resistance.
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AIMS OF THE STUDY
The faecal flora of healthy humans in the community serves as a very important
reservoir of antibiotic resistant bacteria and resistant genes and its key position in
antibiotic resistance epidemiology is generally underestimated. Therefore this thesis
focuses on the prevalence and risk factors for selection and dissemination of antibiotic
resistance among different populations in the community, to provide cpidemiologicul
data for antibiotic policies and if necessary timely interventions.
An ongoing surveillance study determining the prevalence of antibiotic resistance in
the faecal flora of healthy volunteers in the community was analysed for the period
1992 till 1999 and was related to the use of antibiotics in the Dutch community.
Changes in resistance of the normal commensal flora over time can be considered as
an early warning system for resistance to be expected in potentially pathogenic
bacteria. In addition a study was performed to determine the differences of antibiotic
use among different regions in the Netherlands in relation to the prevalence of
antibiotic resistance found. Even within countries differences in the amount of
antibiotics prescribed by general practitioners occur, and consequently may affect the
prevalence of antibiotic resistance between regions.
Besides antibiotic use, the ability of antibiotic resistance to spread is very important in
the development of resistance. If people are living closely together or hygienic barriers
are loose the transmission of resistance bacteria and resistant genes between hosts is
facilitated. Therefore a study was conducted to measure the effect of population
density (as a measure of crowding) in combination with antibiotic use on the
prevalence of antibiotic resistance.
Antibiotic resistance reservoirs like the hospital environment and animal husbandry all
interact in the community. To assess the effect of antibiotic resistance taken home to
the community by hospital patients, a study was performed analysing the prevalence of
antibiotic resistance at different points of time before, during and after hospital
admission. In addition, the genotypic diversity of bacteria isolated from both human
and animal sources was determined to study the transmission between animals and
humans, which may lead to colonisation and subsequently infection in humans.
19
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OUTLINE OF THE THESIS
This thesis attends to the prevalence, the spread and the risk factors of antibiotic
resistance of different populations in the community.
In CHAPTER 2. entitled "Antibiotic use and the prevalence of antibiotic resistance of
healthy volunteers in the Dutch community" antibiotic use in 1996 and 1999 was
related to the prevalence of antibiotic resistance in the faecal indicator bacteria, £". CY;//
and entcrococci isolated from healthy volunteers living in the south of the Netherlands.
The prevalence of resistance was also compared with resistance data from the same
region in 1992.
In CHAPTER 3. entitled "Antibiotic use and resistance in different regions of the
Dutch community" the prevalence of antibiotic resistance of EvcAencA/a co/;' and
cntcrococci isolated from healthy individuals living in three different regions of the
Netherlands was determined and the influence of regional antibiotic consumption on
the prevalence of resistance was studied.
In CHAPTER 4. entitled "The influence of population density on antibiotic resistance"
antibiotic consumption and population density were related to the prevalence of
antibiotic resistant faecal £. ro/i and enterococci of healthy volunteers living in three
cities from three different countries i.e. Canada. Greece, and the Netherlands and
analysed for differences in antibiotic use and population densities.
In CHAPTER 5. entitled "Hospitalisation. a risk factor for antibiotic resistance in the
community" the influence of hospitalisation on the prevalence of faecal antibiotic
resistant £. <•<>/;' was analysed. The prevalence of antibiotic resistance in faecal £. co/i
on admission, at time of discharge, 1 month and 6 months after discharge of patients
admitted to surgical wards of the University hospital Groningen. Maastricht, and
Rotterdam was determined.
20
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In CHAPTER 6. entitled "Difference in genetic homogeneity of vancomycin resistant
and susceptible £n/erococcw.v y&ec»Mm isolated from different human and animal
sources analysed by amplified fragment length polymorphism" the genetic relationship
among 178 vancomycin resistant £/jrerötoccM5 ybfe/wm (VREF) and vancomycin
sensitive £/tferococcM.s /äec/'wm (VSEF) strains isolated from faecal samples of
humans and pigs in the Netherlands and chickens in Greece and the Netherlands was
studied.
21
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ABSTRACT
Although most antibiotics are consumed in the community (80%), the relation of
antibiotic consumption and resistance in the community has been less thoroughly
studied.
In the present study, antibiotic use was related to the prevalence of antibiotic resistance
of £. to// and entcrococci isolated from healthy volunteers living in the south of the
Netherlands in 1996 and 1999.
No change of the total antibiotic use in the Dutch community was observed between
1996 und 1999 (3.542 and 3.59X DDD/1000 inhabitants/year). However, the increased
fluornquinolonc use (+18%) and the increased prevalence of ciprofloxacin resistance
from zero to 2% is a point of concern, especially since this was accompanied by a
significant shift towards higher MIC values (p<0.05). A significant decrease in the
prevalence of vancomycin resistant entcrococci (p<0.05) and a significant shift
towards lower MIC values for avoparcin, a glycopeptide previously used as growth
promoter in animal husbandry, was found (p<0.05). This was very likely the result of
the banning of avoparcin for this purpose from April 1997.
In order to maintain the low level of antibiotic use and resistance in the Netherlands,
surveillance of antibiotic resistance in non-clinical isolates in relation to antibiotic use
is very important.
Key words: community, antibiotic resistance, antibiotic use, £. co//, enterococci.
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INTRODUCTION
Antibiotic resistance has become a major clinical and public health problem. We are
currently faced with (muiti) resistant bacteria that are difficult and sometimes
impossible to treat ', especially in hospitals. However the development of bacterial
resistance is not only confined to hospitals but should be considered an environmental
problem. Especially since most antibiotics are consumed outside the hospital,
accounting for 80% to 90%" of antibiotic use in European countries, selection of
resistant commensal bacteria inevitably takes place in the community \ Besides the
high amounts of antibiotics used in the community for human medicine, approximately
50% of ail antibacterial agents used yearly in the European Union (EU)* and more than
80% in the USA are given to animals'. Based on the observations in several studies
these resistant bacteria and/or their resistance genes can be transferred from animals to
humans either via direct contact e.g. farmers and slaughterers, or indirectly via the
food chain *"*.
There is increasing evidence that commensal intestinal bacteria of humans, but also of
animals play an important, but underappreciated role in bacterial resistance in human
medicine \ Commensal bacteria themselves can cause endogenous infections, but the
main threat is that they can transfer their resistance to potentially pathogenic bacteria
passing through the gut ^''\
In addition, changes in resistance of the normal commensal flora can be considered as
an early warning system for resistance to be expected in potentially pathogenic
bacteria * ' \ Therefore, surveillance of antibiotic resistance in non-clinical isolates in
relation to antibiotic use is important, as it provides epidcmiological data to set up and
control antibiotic guidelines and make timely intervention feasible. In this study,
antibiotic use in 1996 and 1999 was related to the prevalence of antibiotic resistance in
the faecal indicator bacteria. £. co// and enterococci, -the main facultative aerobic
inhabitants of the faecal commensal flora in humans-, "' "• '* isolated from healthy
volunteers living in the south of the Netherlands. The prevalence of resistance was also
compared with resistance data from the same region in 1992 ".
31
CHAPTER 2
MATERIALS AND METHODS
Data on the use of antibiotics was obtained from the Institute of pharmaceutical data
(Stichting Farmaccutischc Kcngctallen, SFK, The Hague, the Netherlands), which has
the most extensive data on antibiotic use outside the hospital in the Netherlands. SFK
retrieves its data from more than 1100 of the 1600 Dutch pharmacies. These 1600
pharmacies served around 91% of the total population in both 1996 and 1999. The
SFK converted the obtained data to an estimate of the total national antibiotic
consumption in the Dutch community in DDD (defined daily dosage) per 1000
inhabitants per year.
In. 19% and 1999, 117 and 171 faecal samples were collected respective/y from
volunteers living in the south of the Netherlands (Weert/Roermond area). Using
randomly selected addresses from the telephone directory written information about
the aim of the study were sent to the participants and they were asked to sent in a
faecal sample on the day of collection together with a questionnaire to the
bacteriological laboratory of the University Hospital Maastricht. The questionnaire
included questions about antibiotic use and hospitalisation three months preceding the
sample collection. For comparative analysis the participants who had used antibiotics
or had been hospitalised in the three months previous sample collection were excluded
for further analysis. Prior to the study approval was obtained from the medical ethical
committee of the University Hospital Maastricht.
A'« »!/>/«'
On the day of arrival at the bacteriological laboratory one faecal sample of each
participant was diluted 1:10 in 0.9% (w/v) NaCl supplemented with 20% (v/v)
glycerol. The diluted samples were stored at -20°C until assayed, as previously
described ' . In short, after thawing the samples were further diluted (10 * - 10" - 10"*)
and 0.04 ml of these dilutions were inoculated onto agar plates without and with
antibiotics using a spiral plater (Eddy Jet, IUL instruments. I.K.S.. Leerdam, The
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Netherlands). The antibiotics and the concentrations used in the agar plates for £. co/i
(cosine methylene blue (EMB)-agar. Oxoid CM 69, Basingstoke. England) are shown
in Table 1. Enterococci (streptococcus KF-agar, Oxoid CM70I, Basingstoke. England)
were tested against erythromycin (10 ug/ml concentration used in the agar plates),
dalfopristin-quinupristin (5 ug/ml). and vancomycin (10 (ig/ml). The concentrations in
the agar plates were based on NCCLS guidelines '* and modified (where appropriate)
to make comparison with previous studies possible '*• ""*'. For enterococci. in addition
to antibiotics used in human medicine also related compounds (previously) used as
antimicrobial performance enhancers (AMGP) were tested.
The prevalence of antibiotic resistance was defined as the number of faecal samples
with resistant £ co// or enterococci divided by the total number of samples tested
multiplied by 100%. To determine the prevalence of dalfopristin/quinupristin resistant
enterococci, the isolates identified as £wfcrocotrw.s /acca//.v were excluded. The degree
of resistance of each sample was defined as the ratio (in %) between the number of
colonies grown on the agar plates with and without antibiotics ".
A//mma/ /nA/A/Vorv
In addition to the prevalence of resistance from one colony of £. co// or cntcrococcus,
isolated from the agar plates without antibiotics, the antibiotic susceptibility as MIC
value was determined using Iso-Sensitest broth™ (Oxoid CM 473. Basingstoke,
England) an inoculum of 5xl0'CFU/ml and an incubation time of 18-24 h at 37°C. £.
co// ATCC 25922 and £«/erococcu.v ybeca/« ATCC 29212 were used as reference
strains. The £. co// isolates were tested against amoxicillin, ciprofloxacin, nalidixic
acid, nitrofurantoin, oxytetracycline and trimethoprim. The enterococci isolates were
tested against amoxicillin, avoparcin. vancomcyin, erythromycin, tylosin and
virginiamycin.
•S/af/.tfica/ ana/vv/5
The chi-square test was used to analyse differences in the prevalence of resistant £.
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£•«// and enterococci sampled in 1992, 1996 and 1999 in Weert/Roermond. The Mann-
Whitney test (2-tailcd, p<0.05) was used to compare the MIC distributions of £. co/i
and enterococci sampled in 1996 and 1999.
RESULTS
No changes in the overall use of antibiotics between 1996 (3,542 DDD/1000
inhabitants/year) and 1999 (3,598 DDD/1000 inhabitants/year) was observed.
However, between 1996 and 1999 an increase in consumption of some groups of
antibiotic was observed: other penicillins (all penicillins besides aminopcnicillins)
(5X9 to 649 DDD/IOOOinh./y), nitrofurantoin (207 to 231 DDD/lOOOinh./y),
lluoroquinolones (261 to 308 DDD/lOOOinh./y), and macrolides & lincosamides (353
to 447 DDD/IOOOinh./y) (Figure I). In addition a decrease in consumption of
aminopcnicillins (800 to 745 DDD/lOOOinh./y), cephalosporins (41 to 27
DDD/IOOOinh./y). tetracyclines (983 to 903 DDD/1000inh/y), trimethoprim (286 to
273 DDD/IOOOinh./y) and quinolones (23 to 16 DDD/lOOOinh./y) was observed. In
both years tetracyclines were the most prescribed antibiotics, followed by
aminopcnicillins and other penicillins (Figure 1).
In 199(i. 117 faecal samples were collected from healthy participants living in the
southern part of the Netherlands of which 13 samples were excluded for further
analysis as they originated from participants who had used antibiotics in the 3 months
preceding sample collection. In 1999. 171 samples were collected from participants
living in the same area. Forty-two of the participants had been hospitalised (n=12)
and/or had used antibiotics (n=35), and therefore, were excluded for analysis. In total
104 and 129 samples were analysed in 1996 and 1999 respectively. The mean age of
the populations analysed in both 1996 and 1999 was 55 years.
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Antibiotic groups
FIGURE 1. Antibiotic use in the Dutch community in 1996 ( & ) and 1999 ( • )
1) Penicillins with extended spectrum
2) ß-lactamase sensitive penicillins. B-lactamase resistant penicillins, combinations of penicillins,
including B-lactamase inhibitors.
3) trimethoprim and combinations of sulfonamides and trimethoprim
No significant differences in the prevalence of resistant £. co// for the antibiotics tested
were found between 1996 and 1999 for the group of participants. A tendency to a
decrease in prevalence was found for amoxicillin resistance from 3X% to 29%,
whereas an increase in prevalence was observed for ciprofloxacin and nalidixic acid
resistance from no resistance in 1996 to 2% and 3% respectively in 1999 (Table I).
The prevalence of enterococci resistant to quinupristin-dalfopristin and vancomycin
decreased significantly over time from 24% and 11% to 12% and 3% respectively
(p<0.05). The prevalence of erythromycin resistant enterococci was 42% and 47% for
1996 and 1999 respectively.
No significant differences in MIC distributions of amoxicilllin, nitrofurantoin.
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oxytetracycline, and trimethoprim were observed between the £. co// isolates from
1996 and 1999. A significant shift to higher MIC values was found for nalidixic acid
and ciprofloxacin (p<0.05) (Table 2). The MIC distributions of the enterococci for
vancomycin, virginiamycin, erythromycin and amoxicillin were similar for the 1996
and 1999 isolates. For both tylosin and avoparcin the MIC distributions of the 1999
isolates showed a significant shift towards lower MIC values (p<0.05) (Table 3).
TABLE I. The prevalence (Prcv.) of antibiotic resistance (%) of faecal
£ic/wWcA/a co// in 1996 and 1999.
Antimicrobial
agent (cone.
Amoxicillin
C'c/a/olin
Ciprofloxucin
C'hloramphenicol
(ientamicin
Nalidixic acid
Nitrofurantoin
Oxytelraeyclin
Trimethoprim
Mg/ml)
(25)
(32)
(4)
(25)
(16)
(32)
(50)
(25)
(8)
19%
n= 104
Pro
38
ni
0
nt
nt
0
0
28
18
1999
n=l29
Pro
29
9
2
9
1
3
0
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DISCUSSION
No significant difference in total human antibiotic consumption outside hospitals was
observed between 1996 and 1999. However, for macrolides and fluoroquinolones an
increase of 27% and 18°o respectively was found and the consumption of
uminopcnicillincs. tetracyelines and trimethoprim slightly decreased.
E. co/i
The increase in prevalence of ciprofloxacin resistance from 0% to 2% in healthy
\nliliiiMu Rcsisi.imi in I In ( omiminitv
volunteers in the present study must be considered as an early warning for prudent use
of fluoroquinolones. especially since a significant shift to higher MIC values for
ciprofioxacin between isolates from 1996 to 1999 was already observed. Also for
nalidixic acid the prototype of the quinolones an increase in prevalence of resistance
and a shift towards higher MIC values was found.
Although in the Netherlands, the prevalence of fluoroquinolone resistant £. ro/i is still
low, there is an increase in the use of fluoroquinolones. From 1990 till 1996
consumption had already increased from 154 to 277 DDD/1000 inhabitants/year
respectively " . As new fluoroquinolones will/have become available for clinical use
an even further increase in use is expected and consequently also a further increase in
the prevalence of resistance * . In several European countries ciprofioxacin resistance
rates in £. co//' increased from less than 1% in 1989 to over 5% in several Huropeun
countries and in a Spanish centre even to 18% " . In the Barcelona community the
prevalence of fluoroquinolone resistance has even reached 22% **.
Both in 1996 and 1999 the prevalence of resistance to nitrofurantoin was zero. Despite
the fact that this compound has been available for clinical use for more than fifty years
a low prevalence of resistance has been reported in many studies all over the world ***'
" . This might be explained by the multiple mechanisms of action of nitrofurantoin on
bacteria " . Also, despite the fact that R-plasmids have been described ", plasmid
mediated resistance of nitrofurantoin remains rare.
In 1992 a similar study was performed analysing antibiotic resistance in £. to// among
healthy individuals living in the same area, using the same method ". Comparing the
prevalence of antibiotic resistant £. co// a significant decrease was observed for
amoxicillin resistance from 1992 (44%) to 1999 (29%) (p<0.05) (Figure 2). This
decrease of amoxicillin resistance is difficult to explain as the consumption of
amoxicillins remained unchanged and high from 1990 till 1996 " . However the use of
amoxicillin with clavulanic acid markedly increased " , eliminating amoxicillin
resistant ß-lactamasc producing £. co//, and thereby possibly lowering the prevalence
of amoxicillin resistant bacteria.
The prevalence of trimethoprim resistant £. co// were of the same size of order in 1996
and 1999 i.e. 18% and 19%, and were higher compared to the 14% in 1992 '*. These
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data could question the empiric choice of trimcthoprim for the treatment of acute
uncomplicated urinary tract infections as recommended by the NHG (Dutch Council
of General Practitioners) *\
H ( . l RK 2. Prevalence of antibiotic resistant £. to// in 1992, 1996 and 1999 in the Dutch
community: 1992 ( K ), 1996 ( • ) . 1999 ( • )
In the present study, the increased use did not result in a significant increase of
erythromycin resistance in enterococci, as macrolides & lincosamides are not the drug
of choice for enterococci infections. The newer macrolides certainly have advantages,
compared to erythromycin, but the worldwide increase in macrolide resistance of 5.
/wcHmwiKK', the most important respiratory tract pathogen, is very likely due to the
increased use of these agents ""• *'.
Tylosin a macrolide antibiotic, used as a growth promoter till april 1997 (EU ban)
showed a significant shift towards lower MIC values from 19% to 1999. However,
although tylosin shows frequent cross-resistance with erythromycin ' no significant
shift towards lower MIC values or a decrease in the prevalence of erythromycin
38
Antibiotic Resistance in the Community
resistance was found. Probably the decrease in use of tylosin was compensated by the
increase in use of macrolides.
In Europe, including the Netherlands, vancomycin is hardly used outside hospitals. In
addition the use of vancomycin in human medicine only slightly decreased in the
Netherlands from 1996 to 1999 (1,145 and 935 DDD I (XX) inhabitants/year
respectively). As previously published, the most plausible explanation for the
significant decrease in the prevalence of vancomycin resistance (p<0.05) is the EU ban
of avoparcin as antimicrobial growth promoter in april 1997 "'.In the present study an
additional shift towards lower MIC values for avoparcin (p<0.05) was observed
reinforcing the effect of the avoparcin ban. Avoparcin. an analogue of vancomycin.
has been widely used as feed additive to promote growth in food animals and this use
has resulted in the transmission of vancomycin resistance from animals to humans via
the food chain *"*. After the ban several studies have described a decrease in
prevalence of vancomycin resistant enterococci *'• '*. In contrast to the previous study
*', in the present study one the volunteers that used antibiotics in the 3 months
preceding sample collection were excluded for analysis. Therefore some differences in
the number of samples and the prevalence of resistant enterococci were observed, but
this does not influence the overall results.
The observed decrease in quinupristin/dalfopristin resistant enterococci from 24% to
12% is most likely due to the fact that virginiamycin, an analogue compound used as a
growth promoter, was in short supply in the Netherlands during 1997 and 1998
because of production problems of the manufacturer *'. However no significant shift
towards lower MIC values was observed for virginiamycin.
All enterococci were found susceptible to amoxicillin. This confirms that amoxicillin
alone or in combination with aminoglycosides remains the drug of choice to treat
enterococcal infections, both vancomycin resistant and susceptible.
In conclusion, in order to maintain the low level of antibiotic use and resistance in the
Netherlands, surveillance of antibiotic resistance in non-clinical isolates in relation to
antibiotic use is important, as it provides epidemiological data to set up and control
antibiotic guidelines and serves as an early warning for resistance in pathogenic
bacteria.
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TABLE 2. MIC distribution of £.co// isolated in 1996 (n= 97) and 1999 (n=l 13)
Antimicrobial
agents
Amoxicillin
Ciprofloxacin*
Nalidixic acid*
Nitrot'urantoin
Oxytctracycline
Trimethoprim
year Percentage of isolates inhibited by concentration (mg/l) ( | = breakpoint) MIC« MIC«, Range
1996
1999
1996
1999
IW6
1W9
1996
1999
1996
1999
1996
1999
0.25 0.5 1 8 16 32 64 128 256 512
100 0
94 1
62
3
0
0
33
14
0
1
87
83
ol
ol
4
52
0
1
71
68
ol
2|
74
69
0
4
1
20
1
2
11
1
0
0
9
3
0
1
0
1
30
20
ll
ol
0
0
11
2|
0
1
ol
ol
67
6K
0
1
0
0
1
0
0
0
0
1
2
8
0
2
6
II
0
0
0
10
ol
ll
0
1
7
4
0
0
0
0
0
5
0
0
8 6
7 20
17
22
4
4
0.25
0.25
0.5
2
16
16
2
2
1
1
256
512
0.25
0.25
1
32
16
16
256
256
32
32
4-512
4-512
0.25
0.25-16
0.5-4
0.5-64
4-32
1-64
2-256
2-256
1-64
1-64
• p<0.05
TABLE 3. MIC distribution of enterococci isolated in 19% (n=97) and 1999 (n= 116)
Antimicrobial
agents
Amoxicillin
Avoparcin*
Vancomycin
Erythromycin
Tylosin*
Virginiamycin
year
19%
1999
1996
1999
1996
1999
1996
1999
1996
1999
1996
1999
Percentage of isolates
0.25 0.5
3
55
26
32
3
12
1
94
96
21
28
73
83
11
II
10
32
63
64
2
2
3
27
12
12
8
24
23
40
30
12
16
inhibited
4
2
0
361
3 I
11
5
111
I6 |
241
131
12
17
by concentration (mgl) ( | = breakpoint)
8
2
0
10
0
2
3
10
6
4
2
III
2 I
16
ol
ol
4
0
ol
ol
1
0
1
0
1
1
32
0
0
0
0
0
0
1
0
0
0
1
1
64
0
0
0
2
0
0
17
11
18
11
0
0
128
0
1
2
2
0
0
MIC» MIC« Range
1
1
•>
0 5
1
1
•>
2
1
1
1
1
8
2
4
->
64
64
64
64
X
4
1-8
1-128
0.5-16
0.5-64
1-128
1-128
0.5-64
0.5-64
0.5-64
0.5-64
1-32
1-32
p<0.05
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ABSTRACT
Regional differences of antibiotic use and antibiotic resistance in the faecal indicator
bacteria M f r i c / i / a co// and cnterococci were determined in different cities in the
south, west and north of the Netherlands. In 1999 differences in antibiotic
consumption were observed between the different regions: 11.19, 10.84 and 7.16 DDD
(defined daily dosage) per 1000 inhabitants per day, respectively. No significant
regional differences were found in the prevalence of antibiotic resistance for both £.
a;// and cntcrococci. However, the differences in antibiotic consumption observed
might lead to changes in antibiotic resistance in the near future. Surveillance of
antibiotic use and antibiotic resistance is strongly recommended to control the
development of antibiotic resistance as it provides epidemiological data to set up and
control antibiotic guidelines.
4S
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liNTRODDCTION
Many studies have proven a relation between antibiotic use and antibiotic resistance in
clinical isolates, especially in the hospital environment/' "' *'" **' '"' *' Although most
antibiotics are consumed in the community (80%), "" the relation of antibiotic-
consumption and resistance in the community has been less thoroughly studied. Use of
antibiotics in the community may lead to an increased resistance in (nonclinicul)
commensal intestinal bacteria.' Besides the fact that commensal bacteria can cause
endogenous infections themselves."*"' ""* they can also transfer their resistance genes to
potentially pathogenic bacteria passing through the human gut/"'**"""
Therefore, surveillance of antibiotic resistance in indicator bacteria of the intestinal
flora of healthy individuals in the community is very important as it can serve as an
early warning system of resistance in pathogenic bacteria.'"' In addition, surveillance of
antibiotic use and antibiotic resistance provides epidcmiological data to set up and
control antibiotic guidelines/' "'"*
The relation between antibiotic use and antibiotic resistance is very complex.
Differences in prescribing habits, antibiotic policies and socio-economic variables can
influence the consumption of antibiotics and consequently the development of
antibiotic resistance. Moreover, the spread of resistant bacteria and resistance genes
can be influenced by several factors such as poor sanitation, crowding, travelling and
grouping of susceptible persons, />., elderly and children/""**
Various studies have analysed the relation between antibiotic use and resistance in
the community, over time,*' **'"'" and between different countries.''' Others described
the effect of altering antibiotic prescribing policies on antibiotic resistance/' '' '*' "
Regional differences of antibiotic use and antibiotic resistance within a country have
been less thoroughly studied ""'".
In the present study, the prevalence of antibiotic resistance of faecal indicator bacteria
£scAer/c/i/o co// and enterococci isolated from healthy individuals living in three
different regions of the Netherlands were determined and the influence of regional
antibiotic consumption on the prevalence of resistance was studied.
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MATERIALS AND METHODS
In the south, west and north of the Netherlands the cities of Weert & Roermond,
Rotterdam and (ironingen respectively were included. Data on the number of
inhabitants, age distribution, population density, and socio-economic variables of the
three regions were obtained from the Central Bureau of Statistics (CBS).
The antibiotic consumption in defined daily doses (DDD) per 1000 inhabitants per day
(DID) in 1999 for the three regions were obtained from the Scientific Institute of
Dutch Pharmacists (SFK, The Hague, the Netherlands). SFK has the most extensive
data on antibiotic use in the Netherlands outside the hospital and retrieves its data from
more than 1100 of the 1600 Dutch general pharmacists. These 1600 pharmacies served
around 91% of the total population in 1999. SFK converts the data retrieved from the
pharmacies of a specific region to estimate the total regional antibiotic consumption.
•Sfwrfv
In 1999, 600 inhabitants from the three cities were randomly selected from the
telephone directory. They were informed by letter about the aim of the study and were
asked to sent in a faecal sample on the day of collection together with a questionnaire
to the bacteriological laboratory of the University Hospital Maastricht. The
questionnaire included questions about age. antibiotic use and hospitalisation three
months preceding the sample collection.
Prior to the start of the study approval was obtained by the Medical Ethical Committee
of the University Hospital Maastricht.
On the day of arrival at the bacteriological laboratory the faecal samples were diluted
1:10 in 0.9% (w/v) NaCI supplemented with 20% (v/v) glycerol. The diluted samples
were stored at -20°C until assayed, as previously described.'* In short, after thawing
the samples were further diluted (10'" - 10"' - 10"*) and 0.04 ml of these dilutions were
inoculated onto agar plates without and with antibiotics using a spiral plater (Eddy Jet.
SO
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IUL instruments, I.K.S., Leerdam. The Netherlands). The antibiotic concentrations
used in the agar plates for both £. co/i (eosine methylene blue(l-MB)-agar. Oxoid
CM69. Basingstoke. England) and enterococci (streptococcus KF-agar, Oxoid CM70I,
Basingstoke. England) were based on NCCLS guidelines and modified (where
appropriate) to make comparison with previous studies possible (Table 3 and 4)."'**
The prevalence of antibiotic resistance was defined as the number of faecal samples
with resistant £. co// or enterococci divided by the total number of samples tested
multiplied by 100. The degree of resistance of each sample was defined as the ratio (in
%) between the number of colonies grown on the agar plates with and without
antibiotics. A ratio > 50% was defined as a high degree of resistance.**
v/.v
The chi-square test was used to analyse the differences in the prevalence and high
degree of resistance between the cities Weert & Rocrmond, Rotterdam and Groningen
in 1999.
RESULTS
In 1999 the population density of the cities Wcert & Roermond (south). Rotterdam
(west) and Groningen (north) was 626 inh./km", 1946 inh./km* and 2046 inh./km*
respectively. The percentage of citizens in the age-groups 0-14 years (17%, 17%,
13%) 15-64 years (66%, 67%, 74%), and more than 65 years (17%, 16%, 13%) was
comparable for the three communities. Furthermore, no clear differences were found
in the number of citizens with a full-time income, which comprised 65%, 66% and
64% of the total population respectively, 4%, 10% and 7% respectively were
unemployed and 15%, 17% and 14% respectively were retired.
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TABLE 1. Regional antibiotic use in the cities Weert & Roermond. Rotterdam, and
Groningen in DDP per 1000 inhabitants per day (DID) in 1999.
Antibiotic groups
Aminopcnicillins'
Other penicillins *
t'ephalosporins
Tctracyclinc»
Trimcthoprim'
Nitrofuranloin
Fluoroquinoloncs
Nalidixic acid
Macrolnlcs
Lincosamidcs
Total
Weert/Roermond
2.49
2.30
0.04
2.95
0.78
0.87
0.75
0.01
1.01
0.04
I I 24
Rotterdam
2.08
2.10
0.09
2.29
0.83
0.59
0.97
0.09
1.77
0.04
10.85
Groningen
1.36
0.82
0.09
2.30
0.81
0.57
0.39
0.16
0.65
0.01
7.16
u) Penicillins with extended spectrum
h) U-luctumase sensitive penicillins, ß-lactamase resistant penicillins. Combinations of penicillins,
including U-lactamusc inhibitors.
c) trimethoprim and combinations of sulfonamidcs and trimcthoprim
The antibiotic consumption in the cities Weert & Roermond (11.24 DID), Rotterdam
(10.85 DID) and Groningen (7.16 DID) in 1999 are shown in Table 1. In general,
aminopcnicillins, other penicillins and tetracyclines were mainly prescribed.
Groningen clearly showed the lowest consumption of antibiotics, especially for the
aminopcnicillins (1.36 DID), other penicillins (0.82 DID), fluoroquinolones (0.39
DID) and macrolides (0.65 DID). In Rotterdam the use of macrolides (1.77 DID) was
high (Table I).
171 Faecal samples were collected from participants living in Weert & Roermond. 133
samples in Rotterdam and 134 samples in Groningen. The response rate ranged from
22% to 29%. The mean age of the populations analysed was 61 (standard deviation
(SD) =15) 61 (SD =17) and 55 (SD =18) years respectively. Thirty-five (20%). 16
(12%) and 9 (7%) of the participants living in Weert & Roermond, Rotterdam and
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Groningen respectively, had used antibiotics in the three months preceding sample
collection. The antibiotics used are depicted in Table 2. The highest antibiotic use (n
=42) was found in Weert & Roermond where amoxicillin (n =13) and doxycycline (n
=8) were mainly prescribed. In the same region, 12 participants were hospitalised in
the three months preceding sample collection, whereas no participants from Rotterdam
or Groningen had been hospitalised.
TABLE 2. Antibiotic use and hospitalisation in thej months prior to sample collection.
(iiomnyenWeert &
Participants /faecal samples (n):
Participants that were hospitalised (n):
Participants that used antibiotics (n):
Antibiotics used:
Amoxicillin
Penicillin
Doxycyclin
Macrolidcs
Trimethoprim
Co-trimoxazol
Nitrofurantoin
Ciprofloxacin
Neomycin
Unknown
Roermond
171
12
35
13
0
8
2
2
0
0
2
0
8
•
Roiicrilam
133
0
16
4
2
3
3
1
2
0
0
0
1
0
9
0
I
1
1
1
I
3
0
1
0
revis/anc?
No significant differences in the prevalence and high degree of resistant E. coli or
enterococci were found between the three regions (Table 3 and 4). For E. coli, the
highest resistance prevalences and the highest degrees of resistance were observed for
amoxicillin, oxytetracycline and trimethoprim (Table 3). The prevalence of
ciprofloxacin resistant E. coli was found highest in Weert & Roermond (2%), whereas
no resistance against this agent was found in Rotterdam or Groningen. Also the
resistance prevalence of nalidixic acid was found highest in Weert & Roermond (4%)
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(Table 3). The prevalence of erythromycin (38%) and oxytetracycline (47%) resistant
cnterococci in Rotterdam was lower compared to the other regions. In all three regions
vancomycin resistant enterococci were isolated at a frequency of 5-6% (Table4).
DISCUSSION
In the present study, regional differences in antibiotic consumption were observed.
The markedly lower antibiotic use in Groningen (7.16 DID) -especially for
aminopcnicillins, other penicillins, fluoroquinoloncs and macrolides- compared to
Wccrt/Rocrmond (11.19 DID) and Rotterdam (10.84 DID) was difficult to explain.
The low use of antibiotics in the city of Groningen, -the capital of the province of
Groningen- was in contrast to the results of Baart ct al. who described the highest use
of antibiotics in the provinces Groningen. Drcnthc and Limburg (10-11 DID).' These
data suggest that the antibiotic policy in the city of Groningen is more restrictive than
in the surrounding region, as in both studies the information on the antibiotic
consumption were obtained from SFK.
The use of macrolides in Rotterdam (1.77 DID) was distinctly higher compared to that
of Groningen or Weert & Roermond. Together with penicillins and tetracyclines,
macrolides are often used for respiratory tract infections.' Although in the Netherlands
macrolide resistance of Sfrcy?fo<Y>a//.v /«it'i/mon/a - the most frequently isolated
respiratory tract pathogen - is still low (4%),"*~ the high use of macrolides in other
Huropean countries like Spain. Italy. Belgium, France and Finland has resulted in high
prevalences of resistance to these agents (24%-53%).'"' ""* In the present study, no
effect of the relatively high macrolide consumption on the prevalence of erythromycin
resistant enterococci in Rotterdam was found yet. However, based on the experiences
in other countries prudent use remains warranted."*
Although nitrofurantoin and trimethoprim are the preferred antibiotics for acute
uncomplicated urinary tract infections, as recommended by the Dutch College of
General Practitioners, a substantial amount of fluoroquinolones were used in all three
regions, being the highest in Rotterdam (0.97 DID). However, no ciprofloxacin
resistant £. to// were found in Rotterdam or Groningen, whereas the prevalence was
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two percent in Weert & Roermond. This percentage is still low. but resistance to
nalidixic acid, the prototype of quinolones. was also high (4%) in Weert & Roermond
and could be used as a sensitive marker for emergence of resistance to
fluoroquinolones.
TABLE 3. Prevalence (Prev.) and high degree (HD) of antibiotic resistance (%) of fuecul
co//'.
Antibiotic, breakpoint
Amoxicillin
Cefazolin
Nalidixic acid
Ciprofloxacin
Chloramphenicol
Gentamicin
Nitrofurantoin
Oxytetracycline
Trimethoprim
(cone. mg/L)
(25)
(32)
(32)
(4)
(4)
(16)
(50)
(25)
(8)
Weert
Prev.
32
9
4
2
9
1
0
33
22
& Roermond
HD
12
1
1
1
4
1
0
11
9
Rotterdam
Pre\
30
7
0
0
s
1
0
28
19
III)
11
0
0
0
1
1
0
11
6
Groningen
Pro
30
II
2
0
6
1
0
33
23
III")
12
1
0
0
2
0
0
10
9
In spite of the regional differences in antibiotic consumption, no significant differences
in the prevalence of antibiotic resistance in both £. t-«// and cnterococci were found
between the three regions. These results are in contrast with two previously performed
studies in the Netherlands that showed regional differences in the antibiotic resistance
of £. to// isolates from urinary tract infections obtained from general practitioners in
the Netherlands.''' ** Even though the relation between antibiotic use and antibiotic-
resistance has been generally accepted, a direct quantitative relationship between the
amount of antibiotic used and the frequency of resistance is still lacking." Several
factors might explain this lack of a direct relationship. First larger differences in
antibiotic consumption might be needed to find a significant difference in antibiotic-
resistance. The more than four-fold higher sales of antibiotics in France, Spain and
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Portugal compared to the Netherlands, Denmark, Sweden and Germany ' do indeed
result in significant differences in antibiotic resistance/
TABLE 4. Prevalence (Prcv.) and high degree (HD) of antibiotic resistance (%) of faecal
entcrococci.
Antibiotic, breakpoint
Amoxicillin
Ciprofloxacin
Erythromycin
Gentamicin
Oxytctracyclinc
Vancomycin
(cone.
(25)
(4)
(10)
(5(K))
(25)
(10)
Weert & Roermond
mg/L) Prcv
0
1
47
4
58
6
. HD
0
0
X
1
15
0
Rotterdam
Prev
1
0
38
5
47
5
HD
1
0
8
1
9
1
Groningen
Prev
1
0
47
5
57
5
HD
1
0
4
1
12
0
Second, historical data on antibiotic use are probably more important than current data
to explain the prevalence of antibiotic resistance. However, the antibiotic use in the
Netherlands, outside the hospitals was more or less constant in the past four years.'
Third the data were analysed on a group level perspective and do not link individual
outcome events to individual exposure histories. '*• '* In the present study on regional
level, antibiotic use was comparable for Weert & Roermond and Rotterdam, but a
higher number of participants (20%) Weert & Roermond used antibiotics compared to
Rotterdam (12%). Also the number of hospitalised participants was higher (n= 12) in
Weert & Roermond. which could have influenced the antibiotic resistance data in this
region. However, the participants (n= 42) that used antibiotics and or were
hospitalised in the three months prior sample collection, showed no significant higher
resistance prevalences (data not shown) compared to their regional counterparts that
did not.
Fourth, next to the use of antibiotics in human medicine a large amount of antibiotics
is used in veterinary medicine, as therapy or feed additives. Approximately 50% of all
antibacterial agents used yearly in the European Union (EU)/ and more than 80% in
the USA are given to animals." causing resistance in their enteric bacteria such as £.
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co// and enterococci. These resistant bacteria and/or their resistance genes can be
transferred from animals to humans via the food chain.'" As no difference in the
exposure of resistant enteric bacteria from bacteria is expected between regions, the
influence of antibiotic use is veterinary medicine on humans is comparable.
Finally, besides the use of antibiotics, the potential of antibiotic resistant bacteria and
resistance genes to disseminate is another very important factor for the prevalence of
antibiotic resistance. With the increase in population in the Netherlands, population
density and urbanisation increased as well facilitating the spread of resistant bacteria
and resistance genes."' **'"" ** Although the population density in Weert & Roermond
was markedly lower than in Rotterdam or Groningen no significant differences in
resistance prevalence were found.
In conclusion, the present study showed no significant regional differences in
antibiotic resistance among the commensal bacteria £. ro// and entcrococci. However,
the observed differences in antibiotic consumption could lead to changes in antibiotic
resistance in the future. Surveillance of antibiotic use and antibiotic resistance is
strongly recommended to control the development of antibiotic resistance as it
provides cpidemiological data to set up and control antibiotic guidelines.
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ABSTRACT
Antibiotic consumption and population density as a measure of crowding in the
community were related to the prevalence of antibiotic resistance of three cities in
three different countries: St. Johns in Newfoundland (Canada), Athens in Greece and
Groningen in The Netherlands. Antibiotic consumption was expressed in DDD
(defined daily dose), as DID (= DDD per 1000 inhabitants per day) and as DSD (=
DDD per square kilometer). The prevalence of antibiotic resistant £. co/; and
cntcrococci was determined in faecal samples of healthy volunteers. In both
Newfoundland and Greece the overall consumption of antibiotics (28 DID) was more
than three limes higher compared to that of the Netherlands (9 DID). The lowest
prevalence of resistant A', <•«// against the majority of antibiotics tested was found for
the samples from Newfoundland and was significant (p<0.05) for cefazolin.
oxytctracyline, and trimethoprim. A poor correlation between the number of DID and
the prevalence of resistance was observed (the Pearson correlation coefficient (Pec)
ranged between -0.93 and 0.87). However, when population density was taken into
consideration and antibiotic consumption was expressed in DSD, a strong correlation
was found (and Pec ranged between 0.86 and 1.00). This study suggests that
population density is an important factor in the development of antibiotic resistance,
and warrants special attention as a factor in resistance epidemiology.
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INTRODUCTION
Several studies have found a positive association between antibiotic use and antibiotic
resistance in the community.'"* However, this is not a direct relationship and therefore
other factors must contribute to the degree of antibiotic resistance observed in a
population .*'*
Besides selection pressure (antibiotic use), dissemination of resistant bacteria and
resistance genes among individuals increase further the extend of prevalence of
antibiotic resistance in a population. Migration of people and increase in population
density through urbanisation set up many opportunities for interpersonal contact
facilitating the spread of resistant bacteria and resistance genes/ and may be an
important factor in the dissemination of antibiotic resistance. So is it well recognised
that dissemination of antibiotic resistant micro-organisms from patient to patient
directly, via instruments or via health care workers, is an important cause of hospital
acquired infections/ but it facilitates also the transmission of resistant bacteria and
genes. Analogous to the hospital situation where patients live closely together in a
relatively small area, population density may be considered a crowding factor outside
the hospital.
In the present study antibiotic consumption and population density were related to the
prevalence of antibiotic resistant faecal EK/JCT/C/;/« fo// and enterococci of healthy
volunteers living in three cities from three different countries i.e. Canada, Greece, and
the Netherlands. £. co/i and enterococci were used as indicator bacteria, because they
represent species of the main facultativily aerobic intestinal flora in humans.'"'*
Part of the study was presented as a poster at the 40th Interscience Conference on
Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-
20, 2000 (abstract 101).
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MATERIALS AND METHODS
The population density of the cities St. Johns (Newfoundland. Canada), Athens
(Greece) and Groningen (The Netherlands) was measured using official published
information from the respective governmental authorities. Antibiotic consumption was
for Newfoundland obtained from IMS Health. Antibiotic consumption in Greece was
derived from Pharmctrica S.A.. a subsidiary of the National Drug Organization of
Greece. The over-the-counter use of antibiotics in Greece was included in the amounts
measured. Antibiotic use in the Netherlands was obtained from the Scientific Institute
of Dutch Pharmacists (SFK). Antibiotic consumption in the community was calculated
for the province of Newfoundland in I99K and for the countries, Greece and The
Netherlands in 1999. The total consumption included the following classes of
antibiotics: penicillins, cephalosporins, macrolides/lincosamides, tetracyclines,
trimelhoprim/sulfonamides and fluoroquinolones (Table 1).
Antibiotic use was expressed as the number of defined daily dose (DDD) consumed
per 1000 inhabitants per day (DID) and as the number of DDD consumed per square
kilometre (km') per day (DSD). The number of DID multiplied by the population
density (the number of inhabitants per km*) is the number of DDD per km* per day.
Faecal samples from residents of the cities St. Johns (NFL), Athens (GR) and
Groningen (NL) were obtained using randomly selected addresses from the telephone
directory. In each city 600 residents were addressed, expecting a response of approximately
30° o. The countries and respective cities were chosen because of their variety in antibiotic use
and population density. Requests with sample bottles were post delivered to the
addresses with a letter stating the purpose of the study.
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The participants were asked to mail or bring their sample on the day of collection to a
local laboratory where two grams of each sample were diluted 1:10 in 0.9% (w/v)
NaCl supplemented with 20% (v/v) glycerol. The participants of Groningen send their
sample directly to the microbiological laboratory of the University Hospital
Maastricht.
The diluted samples were stored at -20°C in the local laboratories and subsequently
those of St. Johns and Athens were transported on dry ice to the microbiological
laboratory of the University Hospital Maastricht.
All further microbiological processing was done in Maastricht as described
previously." In short, after thawing the samples were further diluted. For E. a*//, 40
uL of 10"' and 10""* in 0.9% saline were inoculated on Levine agar plates (EMB-
eosine methylene blue agar, Oxoid CM69, Basingstoke, England) with and without
antibiotics using a spiral plater (Eddy Jet, IUL instruments, I.K.S.. Lecrdam. The
Netherlands). For enterococci, KF-Streptococcus agar plates (Oxoid CM701,
Basingstoke, England) were inoculated with 40 nL of 10'' and 10'dilutions with and
without antibiotics. The antibiotic concentrations used in the agar plates for both E,
co// and enterococci were based on NCCLS guidelines, and are presented in Tables 2
and 3 for £. co// and enterococci respectively. £. co// grows on Levine agar as purple
colonies with a black centre and metallic shine. Only these colonies were counted after
18-24 hours incubation at 37°C. For identification a colony was randomly picked from
the agar plate and were tested for indole and ß-glucuronidase reaction. Previous
studies have shown that £. co// isolates had identical or higher MICs than the
antibiotic concentration of the selective plate they were isolated from. " ' " Enterococci
appear as typical red or pink colonies on KF-Streptococcus agar. After 48 h incubation
at 42°C only the typical pink colonies were counted. The randomly picked enterococci
colonies were identified by using tolerance to bile, esculin hydrolysis, growth in 6.5%
(wt/vol) NaCl, and a positive pyrrolidonylarylamidase reaction (Wellcome). A
previous study has shown that enterococci isolates had identical or higher MICs than
the antibiotic concentration of the agar plate they were selected from . "*
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The prevalence (%) of antibiotic resistance was defined as the number of faecal
samples showing growth of resistant £. co// or enterococci divided by the total number
of faecal samples tested multiplied by 100. The degree of resistance of each sample
was defined as the ratio (in %) between the number of colonies grown on the agar
plates with and without antibiotics.
The study was approved by the Medical Ethical Committee of the University Hospital
Maastricht (no. 97-1-104).
The chi-squarc test was used to determine the significant differences (p £ 0.05, 2-
sided) in the prevalence of antibiotic resistance between the three different
populations. For a valid chi-squarc test all expected frequencies had to be > one and no
more than 20% of the expected frequencies may be less than 5.'^ If the data did not
fulfil these criteria the significant differences were invalid and therefore not tested.
Pearson's coefficient of correlation (Pec) was used to assess the correlation between
antibiotic consumption expressed by the number of defined daily dosage (DDD) per
1000 inhabitants per day (DID) and the number of DDD consumed per square
kilometer per day (DSD) and antibiotic resistance between the three populations. All
analyses were performed in SPSS for Windows.
RESULTS
The population densities of the cities St. Johns, Athens and Groningen were 255
(127,482 inhabitants 499 km"). 8,194 (3,523,407 inh./3.351 km") and 2,046 (171,193
inh./84 km*) inhabitants/km* respectively. The population density of Athens was 4
times higher than Groningen and 32 times higher than St. Johns.
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Faecal samples were obtained from 154, 179 and 129 residents from St. Johns. Athens
and Groningen, with a response rate of 26%, 30%, and 29% respectively. The mean
age (standard deviation) of the participants was 55( 15). 47(2!), and 55( 18)
respectively.
As shown in Table 1 the total use of antibiotics in DDD per 1000 inhabitants per day
(DID) was 3 times higher for Newfoundland (28 DID) and Greece (28 DID) compared
to the Netherlands (9 DID), whereas the total observed use in DDD per square
kilometer per day (DSD) was the lowest for St. Johns (7) DSD followed by Groningen
(19) DSD and by far the highest for Athens (230 DSD).
TABLE 1. Antibiotic use in DDD per 1000 inhabitants per day (DID) and in DDD per square
km per day (DSD) for the province Newfoundland (NFL) and the countries (ircccc ((iR) anil
the Netherlands (NL).
Antimicrobial agents
Aminopenicillins
Other penicillins
Cephalosporins
Macrolides & Lincosamides
Trimethoprim
Tetracyclines
Quinolones
Total
NFL
DID
11
3
4
4
3
1
2
28
DSD
3
0.7
1
0.9
0.8
0.4
0.5
7
GR
DID
6
4
6
7
0.7
3
2
29
DSD
52
33
49
57
5
21
12
229
NL
DID
2
2
0.1
1
0.8
2
0.8
9
DS
4
4
0.2
3
2
5
2
20
For all antibiotic groups Athens clearly showed the highest numbers of DSD, and St.
Johns the lowest, except for cephalosporins, which was lowest in Groningen (0.2
DSD) (Table 1).
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In general, the prevalence of resistance for £. to/i and enterococci for almost all agents
tested was found highest in Athens, followed by Groningen and was found lowest in
St. Johns (Table 2 and 3).
TABI i : 2. l'rcvalcnc
Antibiotic
(cone m^ 1 )
Amoxicillin (25)
Cefazolin (32)
Nalidixic acid (32)
Ciprol1oxacin(4)
Chloramphenicol (4)
(/c7ihi/»k°m () 6)
Nilrofuruntoin (50)
Oxytetracycline (25)
Trimethoprim (8)
* not tested
e ol antibiotic
Prevalence ("
Si Johns
22
3
1
1
1
1
0
16
10
resistance of faecal
•<)
Athens
39
26
12
3
13
2
0
SO
31
(Innungen
30
I I
2
0
6
J
0
33
23
/ . w / ; i /7 i ma co//.
P-value
S/A
0.00
0.00
0.00
•
0.00
•
•
0.00
0.00
A/G
0.11
0.00
0.00
•
0.06
•
*
0.00
0.11
S/G
0.09
0.00
•
*
•
•
*
0.00
0.00
£". <•»//: The prevalence of amoxicillin, chloramphenicol and trimethoprim resistance
was significantly higher (p < 0.05) in Athens compared to St. Johns. The resistance
prevalence of cefazolin, nalidixic acid, and oxytetracycline was significantly higher (p
£ 0.05) in Athens compared to both St. Johns and Groningen. Resistance to cefazolin,
trimethoprim, and oxytetracycline was significantly higher in Groningen compared to
St. Johns. No nitrofurantoin resistance was observed in the three cities (Table 2).
Enterococci: The prevalence of resistance to ciprofloxacin, erythromycin, and
oxytetracycline was significantly higher (p < 0.05) in Athens than in St. Johns and
Groningen. In Groningen resistance to erythromycin. and oxytetracycline was
significantly higher than in St. Johns (Table 3).
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TABLE 3. Prevalence of antibiotic resistance of faecal enterocggcjj
Prevalence (%) P-value
Antibiotic (cone. mg/L)
Amoxicillin (25)
Ciprofloxacin (4)
Erythromycin(lO)
Gentamicin (500)
Oxytetracycline (25)
Vancomycin(lO)
• not tested
St. Johns
1
1
12
2
33
0
Athens
3
13
80
6
88
2
Qroningen
1
0
47
5
57
5
S/A
•
0.00
0.00
0.06
0.00
*
A/G
•
0.00
0.00
0.57
0.00
•
S/G
•
*
0.00
*
0.00
*
an/ft/offc rev/s/anr«
For the majority of antimicrobial agent and resistance combinations in the present
study, a better correlation was found when antibiotic consumption was expressed in
DSD compared to DID (Table 4). For example, the prevalence of amoxicillin resistant
£. co// correlated much better with the number of aminopenicillins in DSD (Pcc= 0.89)
than when expressed in DID (Pcc= -0.39) (Table 4, Figure 1 and 2).
DISCUSSION
The participation rate (26-30%) and mean age of participants (47-55 years) was in the
same order in all three cities. The low response can be partly explained by the
discomfort of sending in a faecal sample. In Newfoundland and Greece the overall
consumption of antibiotics (DID) was three times higher compared to that of The
Netherlands. However, the lowest prevalence of resistance for the majority of
antibiotics tested was found for the samples from Newfoundland. This was significant
for cefazolin, oxytetracyline, and trimethoprim resistant £. co// and erythromycin and
oxytetracycline resistant enterococci.
Antibiotic use is generally considered as the major factor determining the prevalence
of antibiotic resistance in a population. Another important factor contributing to the
development of antibiotic resistance is the dissemination of resistant bacteria or
resistance genes from a resistant donor to a susceptible host, which subsequently can
71
CHMMTT« 4
either become colonised by these bacteria and/or these bacteria might transfer their
resistance genes to bacteria belonging to the intestinal flora of the new host during
their passage trough the intestinal tract. In the hospital it is generally accepted that
patients either colonised or infected with multircsistant micro-organisms must be
isolated to prevent spread of the resistant micro-organisms to other patients. Outside
the hospital a higher prevalence of resistance was observed among persons living in
close contact with pigs and poultry, which have a very high prevalence and degree of
resistance in their intestinal flora due to the excessive use of antimicrobials as growth
promoters and therapy in animal husbandry, i.e. farmers, compared to urban residents
living in the same geographic region .'*
TABI.K 4. The Pearson correlation between the prevalence of resistance and antibiotic use in
1)1)1) per I IHK) mhuhilunls per day (DID) and DDD per km' per day (DSD) for the different
regions.
l're\alenec / ru/; resistance
Amoxicillin
Trimethoprini
Nalidixic acid
C'clazolin
Oxytetracycline
Prevalence enteroeoeei resistance
Lrythromycin
Oxytetracycline
Antimicrobial agent
Aminopcnicillin
Trimethoprim
Quinolones
C'ephalosporins
Tctracyclines
Antimicrobial agent
Macrolidcs
Tetracyclines
Pearson
DID
-0.39
- 0.93
-0.29
0.64
0.87
DID
0.60
0.87
correlation:
DSD
0.89
0.86
1.00
0.93
0.98
DSD
0.87
0.98
This clearly shows that living in an environment with resistant bacteria is a real risk
for acquiring such bacteria and that the closer the contact the larger the risk. Similar to
the hospital environment and living in close contact with food animals one could
speculate that in the community living in close contact with other persons harbouring
resistant micro-organisms or resistant genes is a risk factor to acquire antibiotic
resistance. The commonly observed high levels of resistance among intestinal
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colonisers and clinical isolates in the developing world support cross infection in this
case not only from crowding but mainly from poor sanitation as an important means of
sharing resistant bacteria in many parts of the world. However, it seems unlikely
that in this study differences in hygienic standards have influenced significantly the
prevalence of resistance, since Canada, the Netherlands and Greece are all developed
countries with high and similar sanitation standards.
The results of this study indicate that next to antibiotic consumption population density
is a factor influencing the prevalence of antibiotic resistance in the faecal flora of
healthy individuals in populations. Using population density -as a measure of
crowding in the community- we found a good correlation between the number of DSD
and the prevalence of resistance for the majority of antibiotics. In contrast even
negative Pearson correlation coefficients were found for the consumption expressed in
DID of these agents and the prevalence of resistance. This suggests that the chance for
a susceptible host to pick up resistant bacteria or resistance genes from a resistant
neighbour is higher in areas with a high population density (like CJroningen and
Athens), than in areas with a low population density like St. Johns. Antibiotics are
social drugs but they can only socialise if (susceptible) hosts are in the neighbourhood.
In an area with high antibiotic use by several persons living far apart from each other
(St. Johns) the contribution of the transfer/spread of resistant bacteria to a susceptible
host are lower than in an area where people live next/close to each other.
Not for all drug-resistance combinations a better correlation was found when the
prevalence of resistance was related to DSD instead of DID. Comparable Pec's were
observed for oxytetracycline and macrolides. This could be explained by the existing
high prevalence of resistance of these agents both in Athens and Groningen. Also the
ability of resistance mechanisms to spread can differ, and easy moving genes might
need less population density to disseminate. In the present study however, no
molecular analysis were performed to detect the actual resistance mechanisms of the
isolated organisms.
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FIGURE I. The prevalence of amoxicillin resistant £. ro// ( • ) against
uminopcnicillin consumption in DDD/KKM) inhabitants/day (DID).
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FIGURE 2. The prevalence of amoxicillin resistant £. a;// (•) against
uminopcnicillin consumption in DDD/km'/day (DSD).
In our attempt to point out the importance of crowding in the community as a factor to
facilitate dissemination of resistant bacteria to susceptible hosts and resistance genes,
we recognise that this study has several limitations. Only 3 places were involved and
surely other factors play a role in the development of resistance besides antibiotic use
and population density. For instance the wanner climate in Athens compared to St.
Johns and Groningen, promotes the growth of (resistant) enteric bacteria in the
environment. Apart from human antibiotic consumption the differences in the amount
and kind of antibiotics used in animal husbandry or for crop protection also might have
influenced the prevalence of resistance in the three populations. Moreover the
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correlation between antibiotic resistance and the use of a specific antibiotic agent or
group could have been biased by multiple- or cross-resistance, as the use of one agent
can maintain high levels of resistance to another. However, due to the magnitude of
the differences in antibiotic use, population density and antibiotic resistance between
the 3 places we do not expect that, for example the relatively low response rate, or the
fact that antibiotic use was measured on a country/provincial basis and not regional,
could substantially have influenced the study outcome.
In conclusion this study implies that population density, as a measure of crowding
might be an important actor in the prevalence of antibiotic resistance in populations
and warrants special attention in resistance epidemiology.
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ABSTRACT
The impact of hospitalisation on the prevalence of resistant /-sc/jer/cA/a co// in the
intestinal flora of patients admitted to the surgical wards of three Dutch university
affiliatcd-hospitals was prospectively analysed. Faecal samples were obtained on
admission to the hospital, at time of discharge, and I and 6 months after discharge. All
samples were examined for resistance to 9 antibiotic agents.
For the total patient population no significant differences in the prevalence of
resistance were observed at the different sampling intervals, except for a significant
decrease in ccfazolin resistance between the time of discharge and 6 months after
discharge (10% to 3%, p<0.05). This decrease was mainly observed in patients from
the university hospital Maastricht (azM). in which a significant decrease from 17% to
6% was detected (p<0.05). Moreover, despite dissimilarities in patient characteristics
and the marked variations in antibiotic use, no significant differences in the prevalence
of antibiotic resistance were observed between the three hospitals, except for the
overall higher prevalence of cefazolin resistant £. c«// in azM patients (p<0.05).
In conclusion, in this study, hospitalisation did not seem to have any substantial effect
on the prevalence of antibiotic resistant £. co// at the different time intervals. However
as our study population consisted of patients admitted to the surgical wards, with a
relatively moderate antibiotic use, studies performed in other hospital populations may
produce other results. Therefore further studies regarding the impact of hospitalisation
on the prevalence of antibiotic resistance in the community should be encouraged, as
the understanding of the interaction between different resistance reservoirs is
important for directing future intervention studies.
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INTRODUCTION
Antibiotic resistance is an increasing world wide public health problem. It is generally
accepted that selection of resistant bacteria by the use of antibiotics is the most
important cause of the increase in antibiotic resistance. The hospital is a perfect
environment for the selection and dissemination of antibiotic resistant bacteria.
Twenty-five to 40% of hospitalised patients generally receive antibiotics, either for
therapy or as prophylaxis "*. In addition, the spread of resistant bacteria within the
hospital is facilitated by a high population density, an extensive use of vascular
devices and frequent contacts between patients and healthcare workers '"' '"*• ".
Moreover, underlying illnesses and immunosuppression make hospitalised patients
more susceptible to colonisation and infection by resistant bacteria'" ' \
Many studies have shown that hospitalisation can lead to an increase in antibiotic
resistance in pathogenic bacteria *"*. The effect of hospitalisation on antibiotic
resistance of commensal intestinal bacteria, like Evc-Aer/i/»« co// has received less
attention so far '*" ™. However, resistant commensal bacteria acquired in the hospital
may disseminate in the community through discharged patients, just as community
bacteria may represent a reservoir for hospital outbreaks. The extend of transfer of
resistant bacteria and resistance genes, between these two compartments is unknown,
as to our knowledge studies on this topic arc lacking.
In the present study, the impact of hospitalisation on the prevalence of resistance in
E«:/z?r/c7Ha co// of the intestinal flora of patients admitted to the surgical wards of
three university affiliated-hospitals in The Netherlands was prospectively analysed. £.
co// was used as indicator organism, as this species is one of the dominant acrobically
growing bacteria of the intestinal flora '. The study focused on patients admitted to
general wards rather then ICUs, because patients discharged from the ICU only
represent a very small part of the total number of patients discharged from a hospital.
To assess whether hospital acquired resistance contributes to the dissemination of
resistance genes and resistant bacteria in the community, the prevalence of resistance
was determined on admission, at time of discharge and 1 and 6 months after discharge.
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MATERIALS AND METHODS
From 1999-2001, patients admitted to the participating surgical wards of the university
hospitals of Groningen (azG), Maastricht (azM), and Rotterdam (azR), The
Netherlands, were asked to participate in the present study. Upon inclusion, patients
were requested to collect a faecal sample at the following time intervals; within 24
hours after admission to the hospital, at time of discharge, and I and 6 months after
discharge. Data on antibiotic use and hospitalisation in the three months prior to
hospital admission were recorded. At the time of discharge, the reason for surgical
admission, the length of stay and the antibiotics prescribed were registered for each
patient. One and 6 months after discharge the patients were reminded by mail to send a
faecal sample and were asked to fill in a short questionnaire concerning re-
hospitalisation and antibiotic use in the period between time of discharge and sample
collection. Approval of the Medical Ethical Committees was obtained prior to the start
of the study. Only patients that had given their informed consent were included in the
study.
TABLE 1. Patient characteristics
azG azM azR
Total number of patients 83
Age (mean (SD)) 51 (±16)
Sex (% male) 41%
Antibiotic use in the 3 months prior to admission 25%
Hospitalisation in the 3 months prior to admission 27%
Reason for surgical admission:
vascular surgery 0%
general surgery 25%
oncology 52%
gustro-intcstinal surgery 23%
94
58 (±14)
48%
30%
26%
14%
18%
21%
47» „
91
63(±11)
53%
18%
32%
49%
3%
20%
28%
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Patients were not eligible for the study if they were younger than 18 years; were
unable to give informed consent; had not resided in the Netherlands during the 6
months preceding admission; or were referred from a nursing home (long-term care
facility) or transferred from another ward (in the same or another hospital). Patients
were withdrawn from the analysis; if no faecal samples were obtained on admission, at
time of discharge or one month after discharge; they stayed for less than 2 days in the
hospital; or if they were referred to an intensive care unit for more than 24 hours alter
surgery.
All faecal samples were directly diluted 1:10 in 0.9% (w/v) NaCI supplemented with
20% (v/v) glycerol and stored at -20 °C at the laboratories of the participating
hospitals. Subsequently those of azG and azR were transported on dry ice to the
microbiological laboratory of the azM, where the prevalence of antibiotic resistance
was determined, as described previously ". In short, after thawing, the samples were
further diluted (10* - 10"*) and 0.04 ml of these dilutions were spread over cosinc-
methylene-blue (EMB) agar plates (Oxoid CM 69, Basingstokc, England) without and
with antibiotics, using a spiral plater (Salm and Kipp, Utrecht, The Netherlands). In
the present study, the minimum detection level for £. c«// was 10' colonies per gram
faeces. The antibiotic concentrations used (Table 4) in the agar plates were based on
NCCLS guidelines and modified (where appropriate) to make comparison with
previous studies possible '• '" '*' '*• ". After incubation (37 °C for 18-24 h) the colonies
of £. to// growing on the respective agar plates were counted.
From each EMB agar plate without antibiotics one colony with the morphology of £.
co// was randomly picked to test the indole reaction and the production of ß-
glucuronidase. If both tests were positive the isolate was considered an £. co// and
stored at -70 °C. Identification was confirmed by random selection of 50 £. co//
isolates causing the API 20E system (Biomerieux, s'Hertogenbosch, the Netherlands).
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The prevalence of antibiotic resistance (%) was defined as the number of faecal
samples with resistant £. t-o/i divided by the total number of samples with detectable
£. co// and multiplied by 100. The prevalence of resistance against amoxicillin,
ccfazolin, ciprofloxacin, co-amoxiclav, gentamicin. nalidixic acid, nitrofurantoin,
oxytctracyclinc, and trimcthoprim was determined. The consumption of antibiotics
during hospitalisation in the three patient populations was expressed as the number of
defined daily dosages (DDD) per 100 bed-days. Statistical comparisons were
performed using the chi-squarc test or Fisher's exact test. A p-value < 0.05 was
considered significant.
RESULTS
The overall participation rate of the study was approximately 30%. The most
frequently reported reason for not enrolling in the study were being physically unable
or having psychological reasons. A total of 400 patients were screened for the
exclusion criteria of which 268 were included in the study. From all these 268 patients
faecal samples were collected on admission, at time of discharge, and I month after
discharge (Table 1), and of 221 patients a faecal sample was also collected 6 months
after discharge (azG= 59, azM= 80. azR= 82).
There was no marked variation in the use of antibiotics and hospitalisation in the three
months prior to admission between the three patient populations (Table 1). Almost half
of the azM patients were admitted for gastrointestinal surgery, whereas azR patients
were admitted most often for vascular surgery and azG patients for oncology related
surgery (Table 1). The majority of patients underwent surgery during hospitalisation
(azG=99%, azM=86%. azR=98%). The median length of stay for the populations of
azM. azR, azG was 10, 8, and 6 days respectively.
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TABLE 2. Consumption of antibiotics for systemic use during hospitalisation in the three
patient populations ^_=_^_^_
Antibiotic agent DDD/100 bed-days (number of patients prescribed a .specific antibiotic)
azG azM azR
Aminopcnicillins
Flucloxacillin
Co-amoxiclav
Cefazolin
Ceruroxime
Ceftazidime
Trimethoprim
Cotrimoxazole
Erythromycin
Clindamycin
Aminoglycosides
Ciprofloxacin
Metronidazole
Nitrofurantoin
0.0
0.0
14.8
1.5
0.0
0.0
0.0
0.8
0.0
0.0
2.1
13.7
1.1
0.0
(4)
(11)
(2)
(3)
(17)
(4)
1.4
6.0
94
0.2
0.0
1.1
0.5
0.3
0.0
2.7
4.5
1.3
0.8
0.4
(2)
(3)
(81)
(1)
( I )
(!)
(1)
(3)
(6)
(4)
(1)
(1)
0.1
0.0
21.3
2.0
4.0
0.0
0.0
1.6
2.2
4.4
0.0
5.7
3.3
0.0
45
(1)
(8)
(44)
(8)
(3)
(2)
(3)
(2)
(15)
Total 34 113
Table 2 presents the consumption of antibiotics for systemic use during hospitalisation
in the three patient populations. The use of antibiotics varied substantially among the
three patient populations. The percentages of patients receiving antibiotics in the
patient populations of azM, azR and azG were 93%, 62%, and 34% respectively,
whereas the percentages of patients receiving antimicrobial prophylaxis were 78%,
49% and 34% respectively. In the azM population co-amoxiclav was used for
antimicrobial prophylaxis, and 41% of the patient population also received co-
amoxiclav for therapy. For the azR patients the antibiotics used for therapy were
diverse, whereas cefazolin with or without metronidazol was exclusively used for
prophylaxis. The azG patients were most often prescribed ciprofloxacin for therapy
(18% of the patients) and cefuroxim with or without metronidazol was used for
prophylaxis (Table 2).
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Overall, most faecal samples with detectable £. to// were derived from azM patients
(80%), followed by the patient group admitted to azR (75%), and were lowest among
the azG patients (67%). A significant higher number of azG patients, where no £. co//
could be detected in the faecal samples on admission and discharge, consumed
antibiotics prior to admission and during hospitalisation respectively. Six month after
discharge a reverse association between the prior use of antibiotics and the detection
rate of £.<W/' was observed in the azR patients (p<0.05, Table 3).
£.
In general, comparable percentages of prior antibiotic use and hospitalisation were
found between the three patient populations with detectable £. co// on admission, and
I and ft months after discharge (Table 3). Ninety-two percent of the azM patients
received antibiotics during hospitalisation, which was 61% and 15% for the azR and
azG patients respectively (p<0.05) (Table 3). Almost half of the azM patients with
detectable £. co// (47%) underwent a '(dean-) contaminated' surgical procedure,
whereas the majority of patients from azR and azG underwent 'clean' surgery (75%
and 85% of the cases respectively). A comparable number of the azM and azR patients
were hospitalised for 7 days or more, 53% and 49% respectively, whereas only 25% of
the azG patients were admitted for 7 days or more.
.4 nfiAtVtff<* rI'.vi.v/fl«f<»
Table 4 presents the prevalence of antibiotic resistance for the samples with detectable
/•.'. (•»// on the different time intervals. No significant differences in the prevalence of
resistance were found between admission, time of discharge, and 1 and 6 months after
discharge, both for the total population as for the separate hospitals. One exception
was the significant decrease in the prevalence of cefazolin resistant £. co/i isolated
from the azM patients between discharge (17%) and 6 months thereafter (6%). In
addition, a similar decrease was found for the total patient population (p<0.05). The
azM patients showed a significant higher prevalence of cefazolin resistance on
admission, at time of discharge and I month after discharge compared to the azG
patients and also at time of discharge for the azR patients (p<0.05) (Table 5).
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TABLE 3. Detection rate of faecal £. co// and relation with prior antibiotic use and hospitalisation at the different time intervals.
/4<Ani5.«ion
Total number of patients
Antibiotic use in the preceding 3 months
Hospitalisation in the preceding 3 months
.•If f / w <>/ <//.v</Vfirj;i'
Total number of patients
Antibiotic use during hospitalisation''
/ mon/A «/fiT </i,\r'wrj;<'
Total number of patients
Antibiotic use in the preceding month
Hospitalisation in the preceding month
0 mn/if/iv u/f.r </iv, Miry?
Total number of patients
Antibiotic use in the preceding 5 months''
Hospitalisation in the preceding 5 months
azG
detection
of £. co/i
50
7(14%)'
12(24%)
53
8(15%)'
63
8(13%)
7(11%)
40
14(35%)
5(13%)
no detection
of £. co/i
33
14(42%)
10(30%)
30
20 (67%)
20
4(19%)
2(10%)
19
9 (47%)
2(11%)
azM
detection
of £. co/i
76
21 (28%)
19(25%)
75
69 (92%)
74
10(14%)
7(10%)
63
7(11%)
9(14%)
no detection
of £. co/i
18
7 (39%)
5 (28%)
19
18(95%)
20
3(15%)
0 (0%)
17
2(12%)
2(12%)
azR
detection
of £.co/i
57
11(19%)
16(28%)
71
43(61%)
70
9(13%)
3 (4%)
70
15(21%)*
16(23%)
no detection
of £.co/i
34
5(15%)
13(38%)
20
13(65%)
21
4(19%)
1 (5%)
12
1 (8%)
2(17%)
a) significant difference within a hospital (p^O.OS).
b) significant difference for patients with detectable £. oo/j between the hospitab (p<0.05).
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Hardly any associations were found between the patient related risk factors (age, sex,
antibiotic use, hospitalisation, length of stay, and type of surgery) at the different time
intervals and the prevalence of amoxicillin, cefazolin, and oxytetracycline resistant £.
a;//. The only observed association was for antibiotic use during hospitalisation and
cefazolin resistance at time of discharge (Table S).
DISCUSSION
For the total patient population no significant differences in the prevalence of
antibiotic resistance in £. cW/ were observed at the different sampling intervals.
Moreover, despite the dissimilarities in patient characteristics and the variations in
quantities and types of antibiotics used during hospitalisation, no significant
differences in the prevalence of antibiotic resistance were observed between the three
hospitals, except for cefazolin resistance. A significant decrease in the prevalence of
cefazolin resistance between the faecal samples of azM patients collected at time of
discharge (17%) and 6 months later (6%) was observed. For the total patient
population this also resulted in a significant decrease in cefazolin resistance between
time of discharge and 6 months later. In general, the observed prevalence of antibiotic
resistance in faecal £ «>// on admission was almost similar to the prevalence of
resistance found in faecal £. co//' of healthy volunteers from Maastricht. Rotterdam,
and Groningen in a previous study '.
Although the overall prevalence of antibiotic resistance remains stable at the different
time intervals, the density of colonisation by resistant bacteria in the commensal flora
may increase. This is important, as increasing numbers of resistant bacteria enhances
the chance of dissemination into the environment and to other hosts. However, in the
present study, no difference in the density of colonisation by resistant bacteria was
found at the different time intervals (data not shown).
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TABLE 4. The prevalence (%) of antibiotic resistance per hospital determined for the
samples with detectable £. co//\
Number of faecal
samples with
detectable £. co/i
Amoxicillin (25 mg/L)
Cefazolin (32 mg /L)
Ciprofloxacin (4mg/L)
Gentamicin (16 mg/L)
Nalidixic acid (32 mg/L)
Oxytetracycline (25 mg/L)
Trimethoprim (8 mg/L)
azG
azM
azR
Total
azG
azM
azR
Total
azG
azM
azR
Total
azG
azM
azR
Total
azG
azM
azR
Total
azG
azM
azR
Total
azG
azM
azR
Total
azG
azM
azR
Total
Admission
50
76
57
183
28%
38%
32%
28%
0%'
9%
4%
5%
6%
3%
2%
3%
2%
1%
2%
2%
4%
5%
5%
5%
20%
30%
25%
26%
16%
22%
12%
17%
Discharge
53
75
71
199
30%
36%
41%
36%
0%'
17%
4%'
10%
6%
4%
3%
4%
4%
0%
4%
3%
6%
7%
6%
6%
25%
33%
32%
31".,
17%
23%
24%
22%
After discharge:
1 month
63
74
70
207
39%
34%
39%
38%
2%'
12%
7%
7"u
2%
4%
4%
3%
0%
0%
2%
1%
3%
6%
4%
4%
25%
36%
34%
12%
21%
18%
26%
21%
(i month
40
63
70
173
35%
40%
34%
36%
0%
6%"
3%
3%''
3%
2%
4%
4%
0%
2%
3%
2%
8%
2%
4%
4%
35%
35%
26%
31%
20%
21%
24%
22%
a) No prevalence of resisUnce was found for nitrofurantoin (50 mg/L) and co-amoxiclav (32 mg/L).
b) Significant difTcrence between discharge and 6 months after discharge within a hospital (p-0.05)
c) Significant difference compared to az.M within a time interval (p-'O.OS).
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TABLE 5. The association between hospital-related risk factors and the prevalence of
amoxicillin. cefa/olin. and oxytetracycline resistant £. co/; at time of discharge.
KesiMance prevalence RR 95%C1 P-value
Length of slay
Amoxicillin
Cefa/olin
Oxytetracyclinc
Antibiotic UM yes
Amoxicillin
Cefa/olin
Oxytctracyclinc
Surgery*
Amoxicillin
C'efii/olin
oxytetracycline
a)Unly the patients (n=!89) that underwent surgery are included.
7 d a > s ( n 1 1 1 )
3h%
5%
31%
 (n-120)
39%
13%
30%
clean (n- 124)
37%
5%
32%
£ 7 days (n=88)
36°«
11%
31%
no (n=79)
34%
1%
34%
1.01
2.10
IQP_
1.24
9.87
0.94
0.78-1.46
0.86 - 2.30
0.76-1.5
0.88- 1.69
1.03-3.03
0.74-1.46
(clean-) contaminated (n= 65)
37%
12%
28%
1.02
2.78
0.96
0.78- 1.50
0.91 2.43
0.73-1.52
0.68
0.17
0.69
0.22
0.04
0.84
0.64
0.11
0.78
Selection pressure by antibiotics is considered the most important factor in the
emergence of untibiotic resistance. The azM patients were most widely exposed to
antibiotics. This high use of antibiotics can be explained by the fact that the majority
of azM patients underwent (clean-) contaminated surgery, which because of higher
infection risk is an indication for antimicrobial prophylaxis \ whereas the majority of
a/.R and a/.G patients underwent 'clean' surgery (75% and 85% respectively).
However, the higher selection pressure in azM patients due to the use of co-amoxiclav,
did not seem to have any effect on the observed prevalence of co-amoxiclav or
amoxicillin resistance. The patients that used antibiotics during hospitalisation showed
a significant higher of cefazolin resistance at the time discharge. One might speculate
that the high use of co-amoxiclav induced the increase in cefazolin resistance observed
at time of discharge. The use of cefazolin for prophylaxis in the azR did not seem to
effect the prevalence of cefazolin resistance. The other risk factors that could have
influenced the prevalence of antibiotic resistance like sex. age. antibiotic use. reason of
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surgery, and re-hospitalisation did not display any significant differences at the
different time intervals.
A significant higher number of azG patients that received antibiotics during
hospitalisation had no detectable £. co// in their faecal samples at time of discharge. In
the patient population of the azG ciprotloxacin was frequently used. This drug
eliminates or strongly suppresses intestinal £w/f/-o/>ac7i77ucetje ' and is therefore the
drug of choice for selective decontamination of the gastrointestinal tract. In
combination with the relatively short hospital stay of the azG patients in this study this
might explain the relatively high number of samples with no detectable £. <•»//.
More difficult to explain are the relatively large groups of samples with no detectable
£. co// on admission for both azG and azR patients. As the human commensal flora
generally contains 10*-10* £.co/i per ml faeces in 85% to 90% of the cases \ and the
minimum detection level in the present study was approximately 10 colonies per gram
faeces, the lack of sensitivity of the used methods is not a likely explanation. The
observed differences in the level of detectable £. co// between the time intervals and
the hospitals might have biased the prevalence of antibiotic resistance found.
A reverse relation of antibiotic use and the detect ability of £. co// was observed for
the azR patients 6 months after discharge, where a significant higher number of
detectable £. co// was observed among the azR patients that used antibiotics. Indeed,
antibiotic treatment can have opposite effects on the commensal flora and vary
substantially between agents. For example, amoxicillin can cause an increase of
Enterobacteriae in the commensal flora, whereas fluoroquinolones can eliminate or
strongly suppress them .
In conclusion, and with the exception of cefazolin resistance, hospitalisation did not
seem to have any substantial effect on the prevalence of antibiotic resistant £. co// at
the different time intervals, nor did the large dissimilarities of the patient
characteristics and the variations in selection pressure of antibiotics between the three
hospital populations. However, one can not exclude that resistant bacteria from
hospitals disseminate into the environment and to new hosts once the patient leaves the
hospital ' ". On surgical wards antibiotic use is still relatively low compared to other
wards like haematology or ICUs, which results in a higher selection pressure, and
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perhaps would lead to a more pronounced effect on the prevalence of antibiotic
resistance. In addition, the average length of stay in these wards is usually longer and
patients are often severely immunocompromised. which facilitates dissemination of
and colonisation by antibiotic resistant bacteria.
Studies regarding the impact of hospitalisation on the prevalence of antibiotic
resistance in the community should be encouraged, as the understanding of the
interaction between resistance reservoirs is important for directing future interventions.
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ABSTRACT
The genetic relationship of faecal vancomycin-resistant (VREF) and vancomycin-
susccptiblc £rtfaT0coccw.vyfoc/w/n (VSEF) (n=178) isolated from the same population
of pigs, human healthy volunteers, hospitalised patients (from the Netherlands) and
chickens (from the Netherlands and Greece) was studied by amplified-fragment length
polymorphism (AFLP). The majority of VREF isolated from pigs, healthy volunteers
and hospitalised patients grouped together (genetic similarity >65%). In a previous
AFLP-study by our group the VREF isolated from hospitalised patients grouped
separately, most likely because these were clinical and not faecal isolates as in the
present study. Furthermore. VSEF isolated from humans and pigs were found much
more genetically diverse than VREF. whereas VREF and VSEF from chicken
clustered together in a separate genogroup (genetic similarity > 65%), clearly distinct
from humans and pigs. The present study suggests that pigs seem a more important
source of VREF for humans than chickens, and that human and pig derived VSEF
seem much more heterogeneous than VREF.
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INTRODUCTION
In countries of the European Union (EU) vancomyein resistant entcrococci (VRE) are
relatively frequently found in healthy humans in the community and in farm animals,
and vancomyein resistance is mostly va/j,4-mediated. This considerable pool of
possibly transmissible wi/fc4-mediated glycopeptide resistance in the EU is very likely
caused by the use of avoparcin (an analogue of vancomcyin) as a growth promoter in
animal husbandry until April 1997 '* '*. Occasionally, genetically related VRE isolates
have been found in food animals, meat products . outpatients, and hospitalised
patients suggesting that transmission between animals and humans can occur and may
contribute to colonisation and subsequently infection in humans **' " ' ' \
Thus far, molecular comparison by pulscd-ficld gel clectrophoresis (PFGE) '' " '*' ' \
and amplified-fragment length polymorphism (AFLP) analysis (12, 21) of human- and
animal-derived enterococci has been done only on VRE strains and revealed the
existence of a common human and pig genogroup, while poultry derived VREF
clustered in a separate genogroup. However, typing of the Tn/546 transposon
*"• " showed that identical Tn/546 derivatives were found in humans and poultry
suggesting horizontal spread of the von l^ transposon from poultry to human.
Until now, it is not known whether VREF constitute a separate population within the
£. /aaiwm population, and whether host specific AFLP genogroups are also found
among VSEF. Previous studies mainly focused on the genetic relation between
animals and humans within one country " ' " * ' . In this study, we used AFLP analysis
to study the genetic relationship among 178 vancomyein resistant £w/mwwrw.v
yoedwrn (VREF) and vancomyein sensitive £«/erococcw.v yfer/t/m (VSEF) strains
isolated from faecal samples of humans and pigs in the Netherlands and chickens in
Greece and the Netherlands. AFLP has the ability to establish a genetic relatedness
between strains that, by PFGE, would show no similarity at all. PFGE is the reference
standard for tracing the transmission of strains in hospital outbreaks, but is too
discriminatory to determine genetic relatedness between epidemiological non-related
strains"' .
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The AFLP genogroups defined in the present study were compared to our previous
results of host specific genogroups, among 255 VREF from 9 different countries
isolated from hospitalised patients, nonhospitalised persons and various animal sources
(pigs, poultry, calves, dogs, and cats) *'. Including vancomcyin susceptible enterococci
in molecular epidemiological studies might provide a more extensive insight in the
composition of the cnterococcal intestinal flora in humans and animals and help to
further elucidate the transmission routes and persistence of £. /uec/wm strains from
animals in the human gut' ' .
Part of the study was presented as a poster at the 41st Interscience Conference on
Antimicrobial Agents and Chemotherapy, Chicago, Illinois. December 15-19, 2001
(abstract 1X75).
MATERIALS AND METHODS
All VRliF isolates and a comparable number of VSEF isolates were derived from four
different populations of: 1) healthy individuals (n=537), 2) hospitalised patients
(n=100), 3) pigs (n=!26), and 4) poultry (n=l39). The faecal samples of healthy
individuals were collected from volunteers living in the north (n=129), south (n=171)
and west (n=l 33) of The Netherlands and were selected using random addresses from
the telephone directory in 1999. From the southern region faecal samples of healthy
volunteers were also collected in 1996 (n=104). The faecal samples of hospitalised
patients came from patients admitted to the surgical ward of the University Hospital
Maastricht in 1999. The poultry samples came from Greek (n=50) (kindly provided by
Prof. K. Sarris. Thessaloniki, Greece) and Dutch slaughterhouses (n=89). The last
group of faecal samples were derived from a Dutch pig slaughterhouse. To prevent
multiple sampling from both pigs and poultry from the same farm, faeces were
collected from every 300* or more pig and by collecting only one chicken sample in
the morning and in the afternoon after evisceration at the slaughtering line.
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All faecal samples were diluted 1:10 in 0.9% (w/v) NaCI supplemented with 20% (v/v)
glycerol on the day of arrival at the bacteriological laboratory and were stored at -20°C
until assayed. After thawing the samples, 40 pi of 10-1 and 10 -3 dilutions were
inoculated on KF-Streptococcus agarTM plates (Oxoid CM701; Basingstoke, UK),
with and without (a.o.) vancomycin (concentration: 10 mg/l) using a spiral plater
(Salm en Kip BV. Utrecht, the Netherlands) as previously described "• ". After 48 h of
incubation at 42°C, from each sample one typical enterococcal colony was randomly
chosen from the plates with and without vancomycin and identified using generally
accepted methods'" ".
In total 178 faecal £. /aec/wm isolates were included into the study: 93 VREF and 85
VSEF isolates. Sixty-four isolates were selected from healthy volunteers of which 37
were VREF and 27 were VSEF. Seven VREF and 12 VSEF isolates were derived from
the hospitalised patients. A total of 35 (VREF n=16, VSEF n=19) and 34 isolates
(VREF n=19, VSEF n=15) came from Greek and Dutch poultry farms respectively and
26 isolates were derived from a Dutch pig slaughterhouse (VREF n=15, VSEF n 11).
None of the isolates in the present study were included in our previous study *'.
All 178 isolates were analysed by AFLP. DNA was isolated, as described elsewhere
(20), with the addition of a final ethanol precipitation step to further purify the DNA.
The AFLP analysis and the degree of genetic similarity of >65% for the AFLP patterns
to distinguish genogroups was as previously prescribed *'. This level of 65% was
arbitrarily set and is not an absolute limit, but distinguished four main genogroups and
showed a clear association with the source of the strains. In order to form a specific
genogroup the minimal number of strains needed to be 5. The distinguished
genogroups were compared to the genogroups of our previous study *'.
Gcnotypic diversity based on AFLP typing was calculated by the following equation:
genotypic diversity (GD) =[w/("-l)](l-Lr,), where x, is the frequency of the /th
identical AFLP-type and n is the number of strains *' ". Two isolates were considered
to have an identical AFLP-type when the similarity of banding patterns was >95%.
This cutoff of 95% was based on the previous finding that the degree of similarity
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between quadruplicates of the same organism was 95%-99% "'. When isolates are
highly diverse, no two isolates have an identical AFLP-type, and the calculated GD is
I. When all isolates are identical the GD is 0. Thus an increase in GD suggests an
increased level of genetic heterogeneity.
The chi-square test (2-sided, p < 0.05) was used to analyse the differences in the
distribution of the different experimental groups among the AFLP genogroups.
RESULTS
In total 178 strains, 93 VREF and 85 VSEF originated from different animal and
human sources; healthy volunteers, hospitalised patients, pig and poultry, were
subjected to AFLP typing. Four main groups with strains that shared > 65% of their
restriction fragments were formed as a result of grouping by AFLP. The VREF isolates
from healthy volunteers (35/36), hospitalised patients (6/7) and all VREF from pigs
(15/15) clustered in genogroup A (Figure 1, Table 1) and completely clustered in our
previously reported genogroup A "'.
Compared to the VREF isolates, the VSEF isolates from humans and pigs were
genetically more heterogeneous and were dispersed over the entire dendogram (Figure
1). A significant difference in the distribution of genogroups for the VREF and VSEF
isolated from human volunteers and pigs were found (p<0.05. Table 1). Two new
genogroups E and F mainly consisting of VSEF isolates (11/11 and 8/9 respectively)
were identified in addition to the previous published genogroups "'. The isolates that
clustered in genogroup E were derived from healthy volunteers (9/11) and hospitalised
patients (2/11) and the isolates in genogroup F were isolated from hospitalised patients
(2/9). pigs (4/9) and poultry (3/9) (Figure 1. Table 1).
A total of 15 strains were not assigned to any of the genogroups since they did not
cluster with £ 5 strains. The majority of these strains were vancomycin sensitive
(12/15) and were isolated from healthy volunteers (10/12) and hospitalised patients
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(2 12) (Figure I, Table 1). The genetic heterogeneity of VSEF was also confirmed by
the higher value of the genotypic diversity of the vancomycin-sensitive enterococci
isolated from human volunteers, hospitalised patients and pigs (1.00, 0.97, and 0.95
respectively) compared to that of the vancomycin-resistant isolates (0.77, 0.87, and
0.84 respectively) (Table 2).
The vast majority of the poultry isolates (65/69) grouped in gcnogroup B (Figure 1)
and also completely clustered within the previously reported genogroup B "'. The
poultry isolates grouped clearly separately from isolates recovered from humans and
pigs, irrespective of whether they were VREF or VSEF, or from Dutch or Greek origin
(Figure 1. Table I). This clustering of poultry related VREF and VSEF also means that
the difference in genotypic diversity was smaller between VSEF and VREF from
poultry (0.93 and 0.88. respectively) than VSEF and VRF.F from humans and pigs
(Table 2).
TABLE 1. Distribution of isolates of the different experimental groups among the AI-LI'
genoeroups
AFLP
genogroups
A
B
E
F
Unrelated
Total
No. (%) iof isolates of indicated type in:
healthy volunteers
VREF*
35 (97%
1 (3%)
36
VSEF*
) 6(22%)
2 (7%)
9 (33%)
10(37%)
27
hospital
VREF
6 (86%)
1 (8%)
7
patients
VSEF
5 (38%)
2(15%)
2(15%)
2(15%)
2(15%)
13
poultry
VRll
33 (94%
1 (3%)
1 (3%)
35
pigs
vsr.i \ KI i VSEF*
15 (100%) 5 (46%)
) 32 (94%)
2 (6%) 4 (36%)
2(18%)
34 15 II
* p < 0.05, a significant difference in the distribution of the genogroups for the VREF and VSEF
isolated from human volunteers and pigs were found.
DISCUSSION
In our previous study. 255 VREF strains from different human and animal sources
were subjected to AFLP typing. Four genogroups (A-D), with clustering of isolates
from nonhospitalised volunteers and pigs in genogroup A, chickens in gcnogroup B,
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hospitalised patients in genogroup C. and veal calves in genogroup D were
discriminated ' ' . In the present study, the VREF strains from (nonhospitalised) healthy
volunteers and pigs also clustered in the same genogroup A. However, the strains
from hospitalised patients also clustered in genogroup A, whereas in the previous
study they formed a genetically distinct genogroup C. This observed difference
between the two studies may be explained by the fact that in this study the VREF
derived from hospitalised patients were not clinical isolates from infections or
associated with hospital outbreaks, but were isolates from the faecal flora. Therefore, it
is very likely that the VRHF isolates derived from hospitalised patients were already
acquired in the community, as also found by Endtz et al. (1997) .
I ' M i l . I ' ' . 2 . ( H - I H ' I V p i l . l I l M T M U l l M l l l l l 111 l l l C d l l ' I ' d C M l C \ p c l i m c l l t . l l L T l H i p S .
Source Country* Genetic DIM-IMIY''
Healthy volunteers
Hospitalised puticnts
Pigs
Poultry
"NL the Netherlands.
NL
NL
NL
Nl. .
CiK
C.R
Ci recce
VREF
0.77
0.87
0.84
0.88
VSEF
1.00
0.97
0.95
0.93
*" Numbers indicate the genotypic diversity as calculated by the formula [«/(«-1)](I -Lr,)
The VREF strains derived from healthy volunteers in 1996 and 1999 and from
different regions in the Netherlands showed no specific clustering of AFLP patterns by
year or place, and mainly clustered in genogroup A (specific data not shown).
The genetic similarity found for VREF between human and pig isolates was not present
among the VSEF isolates. Especially, the VSEF derived from healthy volunteers were
genetically more diverse then their resistant counterparts and were spread among genogroup
A. B, and E. In addition. 38% did not cluster in one of the four main genogroups at all. Even
though the number of VSEF derived from hospitalised patients (n=I2) and pigs (n=ll) was
smaller, they also showed more genetic diversity than the resistant strains.
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Re*
Source phcno«> pc C'ountr\
(iroup E
• (iroup B
' (irnup A
(iroup F
FIGURE 1. Dendogram of the genetic similarity of all isolates by AFLP-analysis. Group A,
B, E and F are based on a > 65 % genetic similarity. The dots restore the source, the
vancomycin resistance phenotype and the country origin of the isolates.
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In contrast to the clear distinction between the more homogeneous VREF and more
heterogeneous VSEF strains derived from both humans and pigs, the vast majority of
VREF and VSEF derived from chickens clustered in genogroup B. and displayed a
more or less identical genotypic diversity. Perhaps the antibiotics especially used in
poultry farming have already selected for a specific genetic poultry £. yaec/M/w
population.
The strains isolated from Dutch and Greek chicken present in genogroup B. suggests
that the clustering of strains may be more related to the type of animal they were
isolated from than their geographic origin. However most broilers in the world are not
only genetically related, but also descend from only a few breeding centres. Hence a
common source of contamination cannot be excluded.
The finding of a separate (VREF) poultry group (by AFLP analysis) distinct from
human isolates was also reported in our previous study *'. Also, van den Braak et al.
(IWH) found two major PFGE types of VRE among poultry derived strains that were
not found in the faecal flora of patients '".
These results suggest that clonal transmission of VREF via the food chain from
chicken to humans is less important than from pigs to humans. This might be due to
the fact that chicken specific VREF strains may have difficulty in persisting in the
human intestinal tract. Nevertheless, similar PFGE and AFLP types between turkey
and turkey farmers " "'. poultry and poultry farmers *' have been found indicating that
clonal dissemination of poultry strains to corresponding farmers does occur. For
comparison between different typing methods a subset of strain from this study is
subjected to a multilocus sequence typing (MLST) scheme developed by our group,
and a manuscript describing this MLST scheme for £. /uec/'i/m has been published "*.
In conclusion, human and pig derived VSEF strains are much more heterogeneous
than their resistant counterparts and do not form a single genogroup. The VREF strains
derived from humans and pigs are genetically different from the majority of the VSEF
from pigs and humans and VREF and VSEF from poultry. These results suggest that
pigs are a more important VREF source for humans than chickens by way of clonal
dissemination. Why strains derived from chicken do not seem to persist or survive as
well as pig strains in the human gut remains to be elucidated. More research on strain
KM
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specific traits derived from different human and animal sources -like (virulence
factors), colonisation and persistence abilities- is warranted, as they may play a crucial
role in the transmission and survival of resistant bacteria in the human gut.
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SUMMARY
Antibiotic resistance poses a serious public health threat. Infections caused by resistant
bacteria arc often resistant to more than one antibiotic, and are therefore difficult to
treat and to control. In 1992, the CDC estimated that more than 13 000 hospital
patients in the USA died of antibiotic resistant infections. Since then, the number of
antibiotic resistant infections and associated deaths has risen every year. Until a few
years ago, new antibiotics have always appeared just in the nick of time, before
resistance problems got out of hand. However, now the increasingly rapid pace at
which bacteria develop and acquire new drug resistance profiles, seem to outpace the
rate at which the pharmaceutical industry is able to develop and market new
antibiotics.
In the emergence of antibiotic resistance three stages can be differentiated. First
susceptible bacteria need to acquire resistance either by mutation or by gaining
^«SM'jihttw M'' AVJW .m^r.ttiw? .omtiuu? #««£}> Wh&ltw AhfeSf .<&si>s.tfln.t Attain? ,w.U'
survive and replicate depends in large degree on the selection pressure. If due to the
increasing use of antibiotics susceptible bacteria present are eliminated, their resistant
kin will replace them and the majority of the population will become resistant. The
major selection factor is therefore the volume of antibiotic use. The more antibiotics
are used, the more they select for resistance. Next to selection pressure of antibiotic
use. the dissemination of resistant bacteria and resistance genes is a very important
factor for antibiotic resistance to spread. Dissemination of resistant bacteria through
direct or indirect contact may cause colonisation by drug-resistant bacteria or transfer
of resistance genes to the endogenous flora from one individual to another. The
excessive use of antibiotics by mankind has led to the accumulation of large numbers
of antibiotic resistant bacteria in the environment and the endogenous flora of man and
other animals, that forms an enormous and often underestimated reservoir of resistance
genes for pathogenic bacteria. In fact resistance in pathogenic bacteria should be
considered as only the top of the resistance iceberg.
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Although most antibiotics are consumed in the community (80%), the relation of
antibiotic consumption and resistance in the community has been less thoroughly
studied. In CHAPTER 2. antibiotic use was related to the prevalence of antibiotic
resistant EwAtricAwi co/; and enterococci isolated from healthy volunteers living in
the south of the Netherlands in 1996 and 1999. In this thesis £". co// and enterococci
were used as faecal indicator bacteria belonging to the endogenous flora of humans
and animals. No change in the total use of antibiotics the Dutch community was
observed between 1996 and 1999 (3,542 and 3.598 DDD 1000 inhabitants/year).
However, the increased fluoroquinolone use (+18%) and the increased prevalence of
ciprofloxacin resistance from zero to 2% is a point of concern, especially since this
was accompanied by a significant shift towards higher MIC values (p<0.05).
Furthermore, a significant decrease in the prevalence of vancomycin resistant
enterococci (p<0.05) and a significant shift towards lower MIC values for avoparcin. u
glycopeptide previously used as growth promoter in animal husbandry, was found
(p<0.05). This was most likely the result of the registration suspension of avoparcin
use in animals in April 1997 in the EU.
In CHAPTER 3. regional differences of antibiotic use and the prevalence of antibiotic
resistant faecal £. co// and enterococci, were determined in 3 cities, one in the south
(Maastricht), one in the west (Rotterdam) and the other in the north of the Netherlands
(Groningen). Differences in antibiotic consumption were observed between the regions
of 11.19. 10.84 and 7.16 DDD (defined daily dosage) per 1000 inhabitants per day. for
Maastricht. Rotterdam, and Groningen respectively. No significant regional
differences were found for the prevalence of antibiotic resistance for both £. r«// and
enterococci. However, the observed differences in antibiotic consumption were mainly
for very recently introduced new antibiotics, therefore this might still cause changes in
antibiotic resistance in the near future.
Besides selection pressure (antibiotic use), dissemination of resistant bacteria and
resistance genes among individuals further extend the prevalence of antibiotic
resistance in a population. It is well recognised that dissemination of antibiotic
resistant micro-organisms from patient to patient directly, via utensils or health care
workers is an important cause of hospital acquired infections and also facilitates the
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transmission of resistant bacteria. Analogous to the hospital situation where patients
live closely together in a relatively small area, population density may be considered a
crowding factor outside the hospital. In CHAPTER 4 antibiotic consumption and
population density were related to the prevalence of antibiotic resistant faecal £. co//
and cnterococci of healthy volunteers living in three cities from three different
countries i.e. Canada, Greece, and the Netherlands. In both Newfoundland (Canada)
and Greece (Athens) the overall consumption of antibiotics (28 DDD/1000
inhabitants/day (DID)) was more than three times higher compared to that of the
Netherlands (9 DID). The lowest prevalence of resistant £. co// to the majority of
antibiotics tested was found for the samples from Newfoundland and was significant
(p<0.05) for ccfazolin, oxytctracycline, and trimethoprim. A poor correlation between
the number of DID and the prevalence of resistance was observed (the Pearson
correlation coefficient (Pec) ranged between -0.93 and 0.87). However, when
population density was taken into consideration and antibiotic consumption was
expressed in DSD (DDD/square kilometre/day), a strong correlation was found (and
Pec ranged between 0.X6 and 1.00). This study suggests that population density is an
important factor in the development of antibiotic resistance, and warrants special
attention as a factor in resistance epidemiology.
Many studies have shown that hospitalisation can lead to an increase in antibiotic
resistance in pathogenic bacteria. However the effect of hospitalisation on the
prevalence of antibiotic resistance of commensal intestinal bacteria, like EscAm"c/Ha
co// has been less extensively studied. This was the subject of the study described in
CHAPTER 5. The prevalence of antibiotic resistant faecal £. co// of patients admitted
to the surgical wards of three Dutch university affiliated-hospitals was prospectively
analysed on admission, discharge. I and 6 months after discharge. In the study
performed, hospitalisation on a population level did not seem to have a substantial
effect on the prevalence of antibiotic resistant £. co// at the different time intervals.
Nor did the dissimilarities of the patient characteristics and the variations in selection
pressure of antibiotics between the three patient populations seem to influence the
prevalence of antibiotic resistance. On surgical wards antibiotic use is still relatively
low compared to other wards like haematology or lCUs, which results in a higher
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selection pressure, and perhaps would lead to a more pronounced effect on the
prevalence of antibiotic resistance. In addition, the average length of stay in these
wards is usually longer and patients are often severely immunocompromiscd. which
facilitates dissemination of and colonisation by antibiotic resistant bacteria. Studies
about the effect of hospitalisation on the prevalence of antibiotic resistance in the
commensal flora during and after hospitalisation should be encouraged, as the
understanding of interaction between reservoirs is very important in revealing the
complexity of antibiotic resistance.
Another very important reservoir of antibiotic resistance interacting with healthy
humans in the community, is animal husbandry. In countries of the EU vancomycin
resistant enterococci (VRE) are relatively frequently found in faecal samples of
healthy humans in the community and in farm animals, which very likely caused by
the use ofavoparcin (a glycopcptide antibiotic like vancoinycin) as a growth promoter
in animal husbandry until April 1997. Occasionally, genetically related VRE isolates
have been found in food animals, meat products, outpatients, and hospitalised patients
suggesting that transmission between animals and humans can occur and may
contribute to colonisation and subsequently infection in humans. In C'HAI'TER 6. the
genetic relationship of faecal vancomycin-resistant (VREF) and vancomycin-
susceptible fw/erococcw.v /aec/wm (VSEF) (n=178) isolated from the same population
of pigs, human healthy volunteers, hospitalised patients (from the Netherlands) and
chickens (from the Netherlands and Greece) was studied by amplified-fragment length
polymorphism (AFLP). The majority of VREF isolated from pigs, healthy volunteers
and hospitalised patients grouped together (genetic similarity >65%). Furthermore,
VSEF isolated from humans and pigs were found much more genetically diverse than
VREF. whereas VREF and VSEF from chickens clustered together in a separate
genogroup (genetic similarity > 65%). clearly distinct from humans and pigs. This
suggests that pigs seem a more important source of VREF for humans than chickens,
and that human and pig derived VSEF seem much more heterogeneous than VREF.
Why strains derived from chicken do not seem to persist or survive as well as pig
strains in the human gut remains to be elucidated. More research on strain specific
traits derived from different human and animal sources -like (virulence factors).
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colonisation and persistence abilities- is warranted, as they may play a crucial role in
the transmission and survival of resistant bacteria in the human gut.
The complexity of the various factors involved in the development and spread of
antibiotic resistance can be summarised to 4 stakeholders: the bacteria, the host,
antibiotic use and the environment. The correlation between antibiotic use and
antibiotic resistance has been generally accepted. However, the fact that no clear direct
quantitative correlation between the amounts of antibiotics used and the prevalence of
resistance has been found, underlines the complexity of this observed correlation and
emphasises the importance to study other factors involved. For example, in Chapter 3
the regional differences in antibiotic consumption did not result into marked
differences in the prevalence of antibiotic resistance in these regions, whereas in
Chapter 4 population density as a measure of crowding seemed to have a substantial
effect on the prevalence of resistance found.
In order to maintain the low level of antibiotic resistance and use in the Netherlands,
surveillance of antibiotic resistance on a regional and timely basis in non-clinical
isolates in relation to antibiotic use is important. It provides epidemiological data to set
up and control antibiotic guidelines and serves as an early warning for resistance to be
expected in pathogenic bacteria. Besides the fact that most human antibiotic
consumption takes place in the community, other reservoirs of resistance with a high
use of antibiotics, like the hospital, animal husbandry, day care centres and nursing
homes all interact in the community. Therefore the prevalence and degree of antibiotic
resistance in the commensal flora of healthy volunteers in the community occupies a
key position in resistance epidemiology and should be considered as a very important
source to monitor.
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GENERAL DISCUSSION
All national, European and international bodies, that have made reports or policy
statements on the subject of antibiotic resistance, agree that it is necessary and of
utmost importance to improve surveillance of antibiotic resistance and antibiotic
usage. Global surveillance is necessary, since resistance genes show no respect for
neither geographical nor international borders '. Moreover, global surveillance is the
key to understand the magnitude and trends of resistance and to evaluate the impact of
interventions '. Local surveillance data are, however, important for clinicians needing
guidance for therapy and for the management of local resistance problems \ An
individual hospital may have a different problem from a hospital only a few miles
away.
Local and regional data can provide the basis for national und inlernulionul
surveillance data *• \ Of course there are quite some obstacles in pooling information
obtained locally or regionally to produce overall national data or to compare data
internationally. Problems are bound to be encountered with the I) study design, 2)
selection of populations and bacterial species to be studied, 3) sampling methods, 4)
susceptibility testing methodology. 5) handling and reporting of results, and, last but
not least, 5) funding. This emphasises the importance of collaboration on both national
and international levels, standardisation of methodologies, and of data interpretation
and analysis. Never is the concept of "think globally and act locally' more appropriate
than in this context *.
One of the objectives of surveillance is to guide therapy, but the primary objectives of
bacterial resistance surveillance programmes are to provide data describing the
prevalence and incidence of resistance within populations over time. In addition, the
interaction with other populations as a result of exchange of resistant bacteria or
resistance genes between populations can be assessed. Also the effect of changes in
selection pressure (=antibiotic use) on the prevalence of antibiotic resistance is an
important objective of resistance surveillance. This thesis shows that the prevalence
and degree of antibiotic resistance in the commensal flora of healthy volunteers is
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considered an important, so far mainly neglected, source to monitor. The commensal
flora of healthy volunteers not only gives data on the prevalence of antibiotic
resistance in general, but also provides information on problems that are going to arise
in pathogenic bacteria. Therefore, it not only provides a basis for antibiotic prescribing
and infection control policies, but also for resistance problems that might be
encountered in the community and hospitals. Inevitably, healthy individuals living in
the community will at some point have to attend a general practitioner or will be
admitted to u hospital.
£'. co// and cntcrococci used as faecal indicator bacteria in this thesis belong to the
endogenous flora of humans and animals. They offer several advantages for
population-based surveillance over clinical samples (biased) or zoonotic organisms
(less commonly isolated and therefore less sensitive) due to the relative ease of sample
collection, reproducibility, and the possibility to link prevalence and degree of
resistance to antibiotic use in a population. In addition, the ability to compare
populations makes it easy to study the transfer of resistance between populations and
to target specific populations as reservoirs of resistance. This kind of approach offers a
cost-effective method of surveillance, is easy to standardise and can be used all over
the world.
Even when resistance surveillance data are of good quality, they are frequently not
translated into information for public health action. For too long, the surveillance of
antibiotic resistance has been the territory of a selected and relatively 'closed' circle of
hospital microbiologists, clinicians, and infection control staff and was only aimed at
providing information for therapy and local action and sometimes a scientific
publication. However it provided relatively little to the understanding of the impact of
resistance in terms of rates of morbidity and mortality, and costs. Even though we can
clearly say resistance is costly, there are only a few reports on this subject *\ In order to
convince government authorities to put more funds into confronting this problem, data
on increased morbidity, mortality and costs are essential. There is a need for greater
epidcmiological rigor in resistance surveillance systems so that results can be linked to
the incidence, prevalence and outcome of infection. Resistance data need to be
Summary and General Discussion
transformed into a constant flow of information that can be interpreted by public
health policymakers \
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Infectics veroorzaakt door antibiotica resistente bacterien vormen een toenemend
problcem in de volksgezondheid. Wanneer een infectie veroorzaakt wordt door een
resistente bacterie, kan dit leiden tot falen van een ingestelde antibiotica therapie met
als gevolg einstigere ziektcsymptomen, een verlenging van de ziekteduur en zelfs een
verhoogdc slcrftckans. Bovcndien is kostbaar laboratorium ondcrzoek noodzakelijk
om na tc gaan voor welk antibioticum de bacterie nog wel gevoelig is. Vaak zal er een
van de nicuwere antibiotica gebruikt moeten worden, die een grotere kans op
ongewenstc bijwerkingen hebben en altijd duurdcr zijn. Tot voor kort werd dit niet als
een groot problcem ge/.icn, omdat dc farmaceutische industrie jaarlijks met nieuwe
antibiotica op de markt kwam. Er is echter nog nooit ccn antibioticum ontwikkeld,
wuartegen baetcriän geen rcsistentie ontwikkeld hebben.
Nict allcen is hct aanbod van nieuwe antibiotica heden ten dagc stcrk verminderd.
maar ook komt steeds mccr gccombinccrdc rcsistentie, dus tegen verschillendc soorten
antibiotica, bij bactcriCn voor: de zogenaamdc multiresistcntc bacterien. Met name
voor puticnten op de intensive care met een sterk vcrminderde weerstand en een hoge
vutbaurhcid voor infecties, is het van groot belang dat infecties zeker en snel bestreden
kunnen worden. Bij deze patiönten is vaak geen tijd om uitgebreid en tijdrovend
laboratorium ondcrzoek te doen en dient men in geval van een infectie te kunnen
vertrouwen op een empirisch ingestelde therapie. Als deze therapie faalt bestaat er een
gcrede kans op overlijden van de patiönt. Het geschatte aantal ziekenhuis patienten dat
kwam te overlijden ten gevolge van infecties veroorzaakt door resistente bacterien lag
in dc Vcrenigde Statcn in 1992 op 13 000 gevallen en dit aantal is sindsdien alleen nog
maar toegenomen.
De opkomst van antibiotica resistentie is in drie stappen onder te verdelen. Allereerst
moot ccn bacterie resistentie vergären middels een mutatie of een resistentie gen
overnemen van andere reeds resistente bacterien uit zijn omgeving. Dit gebeurt
spontaan en hicrop is aanwezighcid van antibiotica in het milieu van de bacterie niet of
nauwelijks van invloed. Of deze enkele resistente bacterie vervolgens weer verdwijnt
of uitgroeit tot con resistente populatie hangt in grote mate af van selectiedruk
veroorzaakt door antibiotica. Door het gebruik van antibiotica worden de bacterien die
voor die antibiotica gevoelig zijn gedood of in hun groei geremd, waardoor de
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bacterien die resistent zijn voor dit antibioticum alle ruimte hcbbcn om zieh tc
vermenigvuldigen en de open gevallen plaatsen van de gedode gevoelige bacterifin op
te vullen. Hoe meer antibiotica er gebruikt worden hoe meer sclccticdruk dit tc weeg
zal brengen. en hoe makkelijker het is voor resistente bacterien zieh verder te
ontwikkelen. Naast de selectiedruk van antibiotica, is de disseminatic van resistente
bacterien ook een erg belangnjke factor voor de verspreiding van untibiotica
resistentie. Deze disseminatie kan door direct of indirect contact plaatsvindcn tusscn
gastheren (mens of dier) en kan leiden tot overdracht en kolonisatie van resistente
bacterien of overdracht van resistentie genen aan de eigen baetcric flora van een
nieuwe gastheer.
Antibiotica zijn niet selectief en doden niet a I Icon zieklcverwckkcndc bacterien, maur
iedere gevoelige bacterie die ermee in contact komt. Het grootschaligc gcbruik van
antibiotica gedurende de laatste halve eeuw heeft daardoor niet allcen geleid tot
antibiotica resistentie in pathogene bacterien. maar ook tot grotc aantallen resistcntc
bacterien in de darmflora van gezonde mensen en dicren, en het milieu. Antibioticu
resistentie die wordt waargenomen bij pathogene bacterien is cnkcl het topje van de
resistentie ijsberg.
Er wordt veel onderzoek gedaan naar dc resistentie ontwikkeling van pathogene
bacterien die infecties veroorzaken. aangezien dit natuurlijk een direct effect hectt op
de effectiviteit van het medisch handelcn en falcn van thcrapie. Daarnaast kan het ook
leiden tot een toename in de ernst van de ziekte. ziekteduur cn mortalitcit, maar ook
tot kostenverhoging van de gezondheidszorg. De darmflora als een omvangrijk
reservoir van resistente bacterien en genen, waar (potentieel) pathogene bacterien naar
believen uit kunnen putten wordt echter vaak onderschat. Resistentie waargenomen bij
darmbacterien kan zelfs fungeren als een waarschuwingssysteem voor te verwachten
resistentie in pathogene bacterien. Naast de uitwisseling van resistentie genen van
bacterien die in de darmflora leven of de darmflora enkcl passeren, kunnen
darmbacterien zelf ook infecties veroorzaken. £.vc7w/c/7/a co//, een voornamc
bewoner van de darmflora, is bijvoorbeeld een belangrijkc veroorzaker van
urineweginfecties.
Het ziekenhuis is een unieke omgeving voor de ontwikkeling van antibiotica resistcntc
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bactcriün. Dit komt met name door het hoge antibiotica gebruik (selectie) en de hoge
dichthcid van patiönten en veelvuldige contacten met behandelaars en verpleging, die
kunncn lungeren als transportmiddel (disseminatie). Daarnaast hebben ziekenhuis
paticnten vaak cen vcrmindcrde weerstand. Buiten het ziekenhuis vindt echter het
grootstc gedeclte van antibiotica consumptic plaats, zo'n 80% van het totaal gebruik
door mensen. En dan hebben we het alleen nog maar over het humaan gebruik.
Minstcns zovccl antibiotica worden daarnaast nog gebruikt in de veehouderij en niet
allccn voor bchandeling en prcventic van bacterieic infecties bij zieke dieren, maar
ook als middcl om slachtdicrcn sneller te latcn groeien.
In dit proefschrift is er gekeken naar het voorkomen van resistentie bij darmbacterien
van ge/ondc mensen levend in dc samcnlcving, aangezien de selecticdruk van
antihiotica en risico factoren betrokken bij dc ontwikkcling van antibiotica resistentie
duidclijk vcrder rciken dan zickenhuizen. In de verschillende hoofdstukken is er
gekeken naar de relatic tussen het gebruik van antibiotica in de Nedcrlandsc
samenlcving op rcgionaal niveau (Hoofdstuk 3) en in de tijd (Hoofdstuk 2), het effect
van bevolkingsdichtheid (Hoofdstuk 4) en de rol van ziekenhuisopname (Hoofdstuk 5)
op hot voorkomen van antibiotica resistentie bij darmbacterien. Daarnaast is in
Hoofdstuk 6 gekeken of er genetische verwantschap bestaat tussen resistente en
gevoclige darmbaetcriön gci'solcerd uit mens en dier. m.a.w. zijn resistentie bacterien
in de darmflora van gczonde mensen deels afkomstig van dieren. Hieronder zullen de
bevindingen uit de verschillende hoofdstukken kort besproken worden. In de
hoofdstukken zijn de darmbaetcrign ESC/MT/CA/« CO// en enterococci gebruikt als
indicator bacteric. aangezien zij twee voomamc bewoners zijn van het darmkanaal.
HOOFDSTUK 2. Van 1996 tot 1999 is het totale antibioticagebruik in de Nederlandse
sumenleving vrijwel gelijk gebleven; 3.542 en 3.598 DDD per 1000 inwoners per jaar.
(DDD Staat voor 'defined daily dosage." Een kuur die wordt voorgeschreven door een
huisarts bestaat gemiddeld uit 8.6 DDD.) Er vonden echter wel verandcringen plaats in
de mate van gebruik van bcpaalde soorten antibiotica door de introduetie van nieuwe
antibiotica. Zorgwekkend was de waargenomen toename van fluoroquinolones
gebruik met 18% in combinatie met de waargenomen stijging in ciprofloxacin
resistente £. t-o/i van nul naar 2% in de damiflora van gezonde vrijw illigers. In eerste
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instantie lijkt deze toename minimaal. maar waar eerst geen rcsistentie word
waargenomen. is resistentie nu in opkomst. Hiemaast was er een significantc afname
in het voorkomen van vancomycine resistente enterokokken (VRE) in de darmtlora
van gezonde vrijwilligers. Vancomcyine is een analoog van avoparcine, dat werd
gebruikt als groeibevorderaar in de veeteelt tot April 1997. en een reservoir van VRE
veroorzaakt heeft bij slachtdieren. Antibiotica resistente bacterien bij slachtdieren
kunnen via de voedselketen in de darmflora van mensen terechtkomen (zic paragraaf
Hoofdstuk 6). Het avoparcine verbod heeft dus niet alleen geicid tot een daling van het
voorkomen van VRE in de darmtlora van slachtdieren maar ook tot een significantc
daling in VRE bij de mens. terwijl het vancomycine gebruik bij de mens constant was
gebleven.
HOOFDSTUK 3. Duidelijke regionale verschillen in het gebruik van antibiotica zijn
waargenomen voor de steden Groningen. Maastricht en Rotterdam. Dit gold zowcl
voor het totale gebruik (11.19, 10.84 en 7.16 DDD per 1000 bewoners per dag) als
verschillen in het gebruik van specifieke grocpen antibiotica, zoals het hoger gebruik
van macrolides in Rotterdam (1,77 DDD/1000 inwoners/dag). Wat betreu het
voorkomen van antibiotica resistentie bij zowel £. co// als enterokokken. zijn er echter
geen significante regionale verschillen gevonden in dezc studic. Mogclijk kunnen de
verschillen in antibiotica gebruik in de nabije toekomst wel leiden tot regionale
verschillen in antibiotica resistentie.
HOOFDSTUK 4. Disseminatic van (resistente) bacteriön van patient naar patient
direct of indirect via de verpleging wordt bevorderd door het feit dat in zickenhuizen
de patienten dichtheid hoog is. Buitcn het zickenhuis zou een huge
bevolkingsdichthcid ook opgevat kunnen worden als een bevorderaar voor
disseminatie van bacterien. In Hoofdstuk 4, werd daardoor antibiotica gebruik
uitgedrukt in DDD per vierkante kilometer per dag naast DDD per I (XX) inwoncrs per
dag, voor de steden Groningen (Nederland), Athene (Grickcnland) en St. Johns
(Canada). Er werd een veel sterkere correlatie gevonden tussen het voorkomen van
antibiotica resistentc bactenen in dc darmflora van gezonde vrijwilligers en het
gebruik van antibiotica per vierkante kilometer dan per 1000 inwoners. Deze resultaten
geven aan dat ook bevolkingsdichthcid een belangrijke factor is en medebcpalcnd voor
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de mate van antibiotica resistcntic in een populatie. In de resistentie epidemiologie
dient dan ook hicraan aandacht geschonken te worden.
HOOFDSTUK 5. Zoals vele studies hebben aangetoond is het ziekenhuis een unieke
brocdplaats voor resistente pathogene bacteri£n. Over het effect van zickenhuisopname
op de darmflora van patignten is echter nog niet veel bekend. In Hoofdstuk 5 wordt
een studie beschreven waarbij het voorkomen van resistente £.ro// in de darmflora van
patienten voor zickenhuisopname, bij ontslag en 1 en 6 maanden na ontslag bepaald is.
De studicpopulatic bestond uit patiönten die werden opgenomen op de chirurgische
afdclingcn van de Acadcmischc zickenhuizen in Groningen, Maastricht en Rotterdam.
In dczc studie zijn er geen significantc verschillen gevonden op de tijdstippen waar het
voorkomen van antibiotica resistente £. cW; werd bepaald. Er waren ook geen
duidclijkc verschillen in het voorkomen van antibiotica resistentie tussen de
vcrschillendc zickcnhuispopulatics, ondanks de duidclijke verschillen in populatie
karaktcristicken. Op chirurgische afdclingcn is het antibiotica gebruik laag vcrgeleken
met Intensive Care Units en hematologie afdelingcn. Hier is dus de selectiedruk veel
hoger dan op chirurgische afdclingen. Ook is de ligduur op deze afdelingen hoger en is
de wecrstand van de patiönten veel vaker ernstig vcrminderd. wat de disseminatie en
kolonisatic van antibiotica resistente bacterifin in de darmflora bevordert. en zou
kunnen leiden tot een duidelijker effect op het voorkomen van antibiotica resistentie in
dc darmflora. Nader ondcrzoek naar de invloed ziekenhuisopname op de antibiotica
resistentie in de darmflora bij dit type patient en en de interactie van verschallende
resistentie reservoirs, lijkt dan ook dringend gewenst.
HOOFDSTUK 6. Een belangrijk reservoir van antibiotica gebruik in de samenleving is
het grootschalig gebruik van antibiotica als groeibevorderaar en voor infectie preventie
in de vceteelt. Zoals al eerder besproken heeft het gebruik van avoparcine zeer
waarschijnlijk gcleid tot het voorkomen van vancomycine resistente enterokokken
(VRE) in de darmflora van gezondc Individuen. Genetisch verwante VRE stammen
zijn rcgclmalig gevonden bij varkens. vleesproducten. gezonde individuen, en zelfs
ziekenhuispatienten. Deze bevindingen suggereren een transmissie route tussen dier en
mens, wat betekent dat resistente bacterien afkomstig van diercn kunnen bijdragen aan
de kolonisatie en infecties bij de mens. In hoofdstuk 6 hebben we niet alleen gekeken
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naar de genetische venvantschap van vancomycine rcsistcntc maar ook van
vancomycine gevoelige enterokokken (VSE) afkomstig van verschillende bronnen. Uit
de Studie bleek dat VRE afkomstig van gezonde mensen en varkens sterk verwant zijn,
terwiji VRE afkomstig van kippen een duidelijk aparte groep vormdcn samen met de
VSE afkomstig van kippen. Daarentegen, waren de VSE afkomstig van varkens en
gezonde mensen veel heterogener dan VRE, en was er geen duidelijke clustering van
deze VSE stammen. Deze bevindingen suggereren dat varkens een bclangrijkcrc bron
zijn van VRE voor mensen. dan kippen. Waarom bacteri£n afkomstig van kippen in
tegenstelling tot varkens minder goed lijken te overleven in dc darmflora van dc mens
blijft een vraag. Onderzoek naar specificke karaktcristieken zoals virulcntie factoren,
kolonisatie en persistentic mogclijkhcden van bacteriön afkomstig uit verschillende
menselijkc en dicrlijke bronnen is nodig om de invloed van dezc factoren op de
overdracht en het overleven van resistcntc baetcriön in de darmflora van de mens te
bepalen.
De verscheidenheid in factoren van invloed op de ontwikkcling en vcrspreiding van
antibiotica resistentie kan worden samengevat in 4 ondcrdelen: de bacterie, dc
gastheer, antibiotica gebniik en de omgeving. Alhocwel de rclatic tussen antibiotica
gebruik en antibiotica resistentie algemcen is geacccptccrd, blijft de kwantitatieve
correlatie tussen beide achterwege. Dit benadrukt des te meer de complexheid van het
antibiotica resistentie fenomccn. en benadrukt het belang verder tc kijken dan
antibiotica gebruik in het gevecht tegen antibiotica resistentie. Een duidelijk voorbccld
hiervan staat beschreven in Hoofdstuk 4, waar antibiotica gebruik ailccn geen
duidelijke correlatie vertoonde met het voorkomcn van resistentic terwiji dit wel het
geval bleek wanneer bevolkingsdichtheid bij de vergclijking betrokken wcrd.
Van groot belang voor het behoud van de läge mate van antibiotica resistentic en
gebruik in Ncderland, is het monitorcn van antibiotica resistentie in dc darmflora van
gezonde vrijwilligers in de samenleving zowel op regionaal niveau als in dc tijd. Naast
resistentie gevonden in pathogene bacteriön zouden dcrgclijke epidemiologische data
de basis moeten vormen voor het opzetten en controleren van antibiotica richtlijnen en
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fungeren als een waarschuwingssysteem voor resistentie die op korte termijn verwacht
kan worden in pathogene bacteriän. Behalve het feit dat de grootste hoeveelheid
antibiotica door mensen buiten het ziekenhuis gebruikt worden, vindt in deze open
populatie ook een interactie plaats van verschillende resistentie reservoirs zoals
zickcnhuizcn, kindcrdagvcrblijvcn, verpleeghuizen en intensieve veehouderij. Daarom
dient ondcr/ock naar antibiotica resistentie in de darmflora van gezonde vrijwilligers
ccn slcutclpositic in de resistentie epidemiologie in te nemen en is het niet alleen een
erg bclangrijke bron voor surveillance, maar ook een makkelijk toegankelijke.
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De voorstelling dat dit proefschnft werkelijkheid zou worden leek vaak onwerkelijk.
Toch ligt het hier voor u, maar niet zonder hulp van velen die ik nu zal pogen waardig
tc bedanken.
Allcrcerst mijn copromotoren, Ellen en Ton. Ik kan mij nog goed herinneren dat ik
bcteutcrd bij Ellen op de kamer zat, omdat mijn geplande 2* stage naar Canada op het
laatstc moment niet doorging. Misschicn is het nu niet het juiste moment, maar ik heb
hier ook icmand nodig om met het EMAR (Extramuraal Monitoren van Antibiotica
Rcsistentic) project van start te gaan, was wat Ellen mij zei. Deze kans kon ik niet
taten schicten, aangczicn mijn intcrcssc voor het fenomeen antibiotica resistentic al
ccrdcr was gewekt. Hier ben ik Ellen dan ook erg dankbaar voor. Eenmaal van start als
OK) bij Modische Microbiologic leerde ik Ton al snel kennen. Zo verschillend als Ton
cn Ellen zijn, /o goed vulden zij elkaar aan in het mij bcgeleidcn. In de laatste fasc van
het vervaardigen van dit proefschrift was ik clke keer weer verbaasd over de snelheid
waarmee Ton mijn teksten van commentaar voorzag. zodat ik op mijn beurt ook weer
aan de slag kon. Ellen en Ton bedankt voor alles!
Maar waar was ik geweest zonder de gezclligheid op het lab. de radio aan en zingen en
werken maar. Christel en Nancy als rotsen in de branding, hun kennis en ervaring
zorgde ervoor dat alles in goedc banen geleid werd. Elke, Gilles, Karin, Kim, Sita,
Lucy, Monique, Dominique. Melanie (en iedereen die ik vergeten ben) bedankt voor
het plezierig werken, en jullie mögen de radio houden. Mijn extra dank gaat uit naar
Lucy en Sita, die nog een enorme hoeveelheid werk verstouwd hebben om de
zickenhuis Studie af te kunnen ronden, terwijl ik al op het RIVM zat. Soms was het
niet allemaal even duidelijk. mijn excuses hiervoor. maar jullie hebben het voor elkaar
gekregen! Op de kamer was vaak wisseling van de wacht, maar Daisy was er altijd. en
ik kon haar ook altijd stören met vragen of een goed gesprek. Na een gesprekje met
Daisy leck alles altijd een stuk makkclijker.
Het EMAR project, waar dit proefschnft uit gerealiseerd is. wcrd uitgevoerd in
samenwerking met de afdeling Modische Microbiologie van het academisch
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ziekenhuis Groningen en Rotterdam, mijn dank dan ook aan John Degener (azG),
Hubert Endtz en Margreet Filius (azR).
De coauteurs in dit proefschrift wil ik natuurlijk ook hartelijk bedanken voor hun
expertise. Speciaal wil ik hierbij Rob Willems bedanken die naast al /ijn kennis, ook
zijn lab beschikbaar heeft gcsteld. Ook wil ik Margreet Filius extra bedanken voor
haar kritische blik en gezellige besprekingen, die niet alleen over werk gingen, maar
ook over bijvoorbeeld huizen kopen. Inmiddels zijn wc allebei trotsc huiseigenaars.
Verder, niet te vergeten, mijn paranimfen Margreet en Lucy, bedankt dat jullie mij bij
willen staan!
Verder wil ik bedanken; Auke voor de prachtige kaft, Patricia en de rest van het
Secretariaat Medische Microbiologie voor hun behulpzaamheid. Linda Wildeboer voor
de werving in Groningen, mijn CIE collega's op hei RIVM voor hun open ontvangst
op de afdeling, natuurlijk het HARSS team, waar ik dankbaar deel van uitmauk, en alle
vrijwilligers die hun poepje hebben ingestuurd!
Mijn dank gaat natuurlijk ook uit naar mijn ouders die mij de kans hebben gegeven om
te gaan studeren en samen met mijn zus Femke erg betrokken zijn geweest bij het wel
en wee van dit proefschrift. Daarbij ben ik ook erg blij dat mijn vrienden het met me
hebben uitgehouden in deze toch wat hectische tijd en dat het maar een mooi feestje
mag worden 12 december. Erik Jan, jij was mijn rustpunt. Wanneer het soms wat veel
werd allemaal. was jij daar altijd die de boel heerlijk relativeerde en de bomen weer
zichtbaar maakte.
Nienke
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Nienke Bruinsma werd op 26 augusrus 1976 geboren tc Son. Van 1989 tot 1994
volgde zij haar middelbare schoolopleiding aan het Lorentz-Lyceum te Eindhoven. In
1994 begon zij met haar Studie Gezondheidswetenschappen aan de Universiteit
Maastricht, waar zij in januari 1999 haar Doctoraal Diploma hchuuldc. Tijdcns haar
stage deed zij onder supervisie van Dr. E. E. Stobberingh cen onderzock naar
shuntinfecties bij kinderen tot 6 jaar. behandeld voor hydrocephalus, in het acadcmisch
ziekenhuis Maastricht (azM). Van januari 1999 tot Oktober 2001 was zij werk/aam als
onderzoeker in opleiding bij de afdeling Medische Microbiologie van het azM. Hier
heeft zij zieh ingezet voor het EMAR project, Extramuraal Monitoren van Antibiotica
Resistentie. Vanaf Oktober 2001 is zij werkzaam bij het Rijksinstituut voor
Volksgezondheid en Milieu (RIVM) waar zij epidcmioloog is bij hct European
Antimicrobial Resistance Surveillance System (EARSS).
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